

## **CURRICULUM VITAE**

**Dr. GENOVEFFA FRANCHINI**

National Cancer Institute/Center for Cancer Research  
Vaccine Branch  
9000 Rockville Pike  
Building 41, Room D804  
Bethesda, MD 20892-5065  
301-496-2386 (Main)  
301-402-0055 (Fax)  
Email: franchig@mail.nih.gov

### ***Citizenship***

United States

### ***Education/Training***

1977 - M.D., University of Modena, Italy

### ***Board Certification***

1981 - Board of Hematology

### ***Current Position***

Chief, Animal Models and Retroviral Vaccines Section, Center for Cancer Research, National Cancer Institute

### ***Description of Current Position***

Dr. Genoveffa Franchini is a renowned Retrovirologist who has pioneered research on oncogenes and human retroviruses (HTLVs and HIVs). She has made numerous achievements in virology and translational approaches to prevent and treat human diseases caused by retroviruses. Her work has furthered the understanding of HTLV-1 pathogenesis, leading to the identification and characterization of new viral genes (*PNAS* 1992) and their function (*Nature Medicine* 2003). Recognition of her achievements includes an invitation to write the HTLV-1 chapter in the 2007 edition of the standard reference *Fields Virology*.

Her accomplishments in HIV vaccine development have secured patent rights to the U.S. Government on the use of poxvirus vectors alone or in combination with DNA. One of the vaccines developed, was tested in Dr. Franchini's laboratory clinical trials on 16,000 volunteers in Thailand. Dr. Franchini's laboratory genetically characterized SIV (*Nature* 1987), and defined the regulatory function of HIV-1/2 and SIV genes (*Science* 1986, 1990). She first demonstrated the importance of Vpr in HIV-1 infectivity in macrophages (*PNAS*, 1990) and the SIV fusion peptide (*Science*, 1989). Her work in immunological mechanisms furthered the understanding of vaccine efficacy and protection (*Nature Medicine*, 2005). In the therapeutic arena, Dr. Franchini provided the first proof of principle that vaccination provides transient benefit to SIV-infected macaques (*Nature Medicine*, 2001), and she pioneered strategies to down-modulate regulators of immune response in HIV-1-infected individuals.

Dr. Franchini serves the scientific field through editorial duties for peer-review journals, including *Journal of Virology*. She is an Associate Editor for *Blood*, *Mucosal Immunology*, and *AIDS Reviews*. She is in frequent demand to review manuscripts for prestigious journals including: *Journal of Clinical Investigation*, *Journal of Experimental Medicine*, *Journal of Immunology*, *Journal of Infectious Diseases*, *Journal of Virology*, *Nature Medicine*, *Nature Reviews Immunology*, and *Oncogene*. Dr. Franchini serves on search and thesis committees, has served ad hoc in several study sections and has chaired the HIV-Vaccine study session in the last year and half. She serves on scientific committees, faculties, and advisory and review boards in intramural and extramural capacities. She has a strong mentorship record with former fellows, and now serves in important scientific positions at Harvard University, Institut Pasteur, in private industry, and at respected education and research institutions throughout the United States, Europe, and South America.

### ***Research Interests***

HTLV-1 causes ATLL and a progressive myelopathy designated TSP/HAM. HIV-1 is the causative agent of AIDS. Both of these human retroviruses induce disease affecting CD4+ T cells. Major research interests are: (1) To investigate how HTLV-1 proteins subvert cellular and physiological pathways of T cells and lead to their transformation and (2) To develop strategies for preventive vaccines and therapeutic vaccines for HIV-1.

### ***Positions Held***

- 1997 - Present: Chief, Animal Models and Retroviral Vaccines Section, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD
- 1995 - 1996: Acting Chief, Laboratory of Tumor Cell Biology (LTCB), NCI, NIH, Bethesda, MD
- 1993 - 1996: Chief, Section on Animal Models and Retroviral Vaccines, LTCB, NCI, NIH, Bethesda, MD
- 1988 - 1992: Visiting Scientist, LTCB, NCI, NIH, Bethesda, MD
- 1986 - 1988: Guest Researcher, LTCB, NCI, NIH, Bethesda, MD
- 1982 - 1986: Visiting Associate, LTCB, NCI, NIH, Bethesda, MD
- 1979 - 1982: Fogarty Fellow, LTCB, NCI, NIH, Bethesda, MD
- 1977 - 1979: Postdoctoral Fellow, Hematology Institute, University of Modena, Italy

### ***Memberships***

- Member, Italian Society of Haematology - 1982-2015
- Member, Italian Society of Medicine - 1981-2015
- Member, American Society of Clinical Investigation (elected member) - 1990
- Member, International Retrovirology Association - 1980 - 2015
- Member, International Association for Comparative Research on Leukemia and Related Diseases – 1985 -2015
- Member, American Association of Physicians (elected member) - 2007
- Service Member, HIV/AIDS Vaccine Study Section, 2005
- Member, American Society of Hematology - 2008

### ***Editorial work***

- Associate Editor for AIDS Review – 1995 - 1998
- Associate Editor for Mucosal Immunology (Nature Publishing Group) – 2004 - 2015
- Associate Editor for Blood (American Association of Hematology), 2008 – 2015

### ***Editorial Board Membership***

- AIDS Research and Human Retroviruses
- AIDS Treatment Strategies
- Journal of AIDS
- Journal of Virology
- Vaccine
- Virology
- AIDS Abstracts

### ***Honors & Awards:***

- National Institute of Health Award of Merit, 2011
- National Cancer Institute Mentor of Merit Award, 2001, 2009
- Federal Technology Transfer Act Award, 1994-1997, 2001-2008, 2010-2014
- Outstanding Mentor Award, NCI Fellowship Office, 2001, 2004, 2009, 2010, 2011
- National Cancer Institute Director Award, 2011
- Dale McFarlin Award, 17<sup>th</sup> International Conference on Human Retrovirology: HTLV and Related Viruses
- Center for Retrovirus Research Distinguished Research Career Award, Center for Retrovirus Research of The Ohio State University 2016

### *Invited Guest Lectures/Presentations*

Professorship; University of Kumamoto; Japan; 1994

Professorship; Pasteur Institute; Paris, France; 1994

Guest Lecturer, New Insights on HTLV-I Origin and Pathogenesis; Laboratory of Dr. Myron Essex; Harvard School of Public Health; Boston, MA; August 1995

Guest Lecturer, Insights on HTLV-I/II Natural History and Pathogenicity; Laboratory of Dr. Ronald C. Desrosiers; Harvard Medical School; Boston, MA; December 1995

Invited Participant, Symposium on Virological and Immunological Features of HIV-Infected Long Term Non-Progressors; Milan, Italy; May 1996

Invited Participant, International Agency For Research On Cancer Working Group on HTLV and HIV Monographs; Lyon, France; June 1996

Guest Lecturer, HIV-I Vaccine Development; University of Vienna Medical School; Vienna, Austria; September 1996

Guest Lecturer, HTLV-II Pathogenesis; University of Padova; Padova, Italy; September 1996

Guest Speaker, Evaluation of a NYVAC-SIV Vaccine in the Macaque Model; Institute of Human Virology, University of Maryland; Baltimore, MD; February 1997

Invited Participant, International Meeting on Herpes Virus; Pisa, Italy; May 1997

Invited Participant, 10th Symposium on Molecular Biology of Hematopoiesis; Hamburg, Germany; July 1997

Invited Speaker, XIX Symposium of the International Association for Comparative Research on Leukemia and Related Diseases; Mannheim/Heidelberg, Germany; July 1997

Invited Participant, 15th Annual Symposium on Nonhuman Primate Models for AIDS; Seattle, WA; September 1997

Guest Lecturer, 1997-1998 External Seminar Series; John P. Robarts Research Institute; London, Ontario, Canada; October 1997

Invited Participant, Invitation of Foreign Scientists to Japanese Institutes, Japan Health Sciences Foundation, Kagoshima, Japan, 1998

Lecturer, Second National Hematology Blood Transfusion Meetings, Vietnam Society Hematology Blood Transfusion, Ho Chi Minh City, Vietnam, 1998

Invited Lecturer, Primate Evaluations of AIDS Vaccines Workshop, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 1998

Invited Lecturer, V International Symposium on HTLV in Brazil and IX Meeting of Hematology and Hemotherapy of Ceara; Fortaleza, Brazil, 1998

Lecturer, 12th World AIDS Conference, Geneva, Switzerland, 1998

Invited Lecturer, 17th UICC International Cancer Congress, Rio de Janeiro, Brazil, 1998

Invited Lecturer, Lindsley F. Kimball Research Institute, New York, NY, 1998

Invited Lecturer, 9th International Conference on Human Retrovirology: HTLV, Kagoshima, Japan, 1999

Invited Lecturer, U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, 1999

Invited Lecturer, International Symposium on HIV, Leukemia, and Opportunistic Cancers; Marrakech, Morocco, 1999

Invited Lecturer, XXVI Congress of Polish Pediatricians, Mikolajki, Poland, 1999

Invited Participant, Immune Based Interventions in HIV Infection and Treatment: A Promising Approach Seminar, NIH AIDS Interest Group, Bethesda, MD, 1999

Invited Participant, HIV Therapeutic Vaccines in the HAART Era NIH Seminar, Boston, MA, 1999

Invited Participant, MHC Typing Issues and Breeding of Genetically Defined Nonhuman Primates for AIDS Vaccine Studies Workshop, NIH, Office of AIDS Research, Bethesda, MD, 1999

Invited Participant and Speaker, Immune Reconstitution: Facts and Challenges, Clinical Research Institute of Montreal; Montreal, Quebec, Canada, 1999

Invited Participant and Speaker, 12<sup>th</sup> Colloque Des Cent Gardes, Paris, France, 1999

Invited Participant and Speaker, 7<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2000

Invited Participant, UCSF AIDS Research Institute and Vaccine Research of Chiron Corporation Think-Tank Session on HIV Immunization Strategies, San Francisco, CA, 2000

Invited Speaker, Wistar Institute Lecture Series, Philadelphia, PA 2000

Invited Participant, HIV Therapeutic Vaccines in the HAART Era NIAID Workshop, Rockville, MD 2000

Invited Lecturer, III Meeting on Pathogenesis, Diagnosis, and Treatment of HIV Infection, Division of Infectious and Tropical Diseases, IRCCS Policlinico San Matteo; Vienna, Austria, 2000

Invited Speaker, IX Annual Meeting of the Canadian Association for HIV Research; Montreal, Canada, 2000

Participant, HIV/AIDS Vaccine Development Workshop, Paris, France, 2000

Invited Participant and Lecturer, Viruses in the Etiology of Human Cancers Meeting, Heidelberg, Germany, 2000

Invited Speaker, American Association of Immunologists and Clinical Immunology Society Joint Annual Meeting: Immunology 2000, Seattle, WA, 2000

Invited Speaker, AIDS Vaccine Evaluation Group & HIV Vaccine Trials Workshop, Washington, DC, 2000

Invited Speaker, Rationale and Prospectives of Immune Intervention in HIV Workshop, Paris, France, 2000

Invited Speaker, AIDS Research Institute and Center for AIDS Research (UCSD) Lecture Series, San Diego, CA, 2000

Invited Lecturer, Mt. Sinai School of Medicine Lecture Series, New York, NY, 2000

Invited Speaker, Mid-Atlantic SIV Interest Group Re-educating the Immune System in Primate Immunodeficiency Virus Infection Meeting, Frederick, MD, 2000

Speaker, Symposium on Nonhuman Primate Models for AIDS, Madison, WI, 2000

Keynote Speaker, Structured Treatment Interruptions Workshop; Chicago, IL, 2000

Lecturer, XIV Convegno Nazionale AIDS e Sindromi Correlate, Milan, Italy, 2000

Chairperson, Viral Diseases in Hematology Session, Part of the 2000 American Society of Hematology Education Program, San Francisco, CA, 2000

Invited Participant, Immune-Based Therapies & HIV Disease Meeting, Forum for Collaborative HIV Research, Center for Health Services Research & Policy, George Washington University Medical Center Washington, DC, 2000

Lecturer, Adult AIDS Clinical Trials Group Retreat, Therapeutic Immunology Subcommittee, Immunology Research Agenda Committee, NIH, Washington, DC, 2000

Speaker, Lecture Series of the Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, 2000

Lecturer, 6<sup>th</sup> Glasgow Virology Workshop, Glasgow, Scotland, 2001

Lecturer, University of Rome; Rome, Italy, 2001

Lecturer, University of Padova; Padova, Italy, 2001

Speaker, Wistar Institute Seminar Series, Philadelphia, PA, 2001

Speaker, Children's Hospital of Philadelphia Seminar Series, Philadelphia, PA, 2001

Chairperson, Immune Reconstitution and Surrogate Markers in HIV/AIDS Workshop, Institute of Human Virology, Baltimore, MD, 2001

Invited Speaker, HIV Immune Based Therapies Symposium, Boston, MA, 2001

Lecturer, Pathogenesis, Diagnosis, and Therapy of HIV Infections (organized by Policlinico San Matteo IRCCS, Pavia, Italy), Venice, Italy, 2001

Lecturer, 10<sup>th</sup> International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 2001

Lecturer, Mahidol University, Bangkok, Thailand, 2001

Lecturer, Blood Transfusion Hematology Center, Ho Chi Minh City, Vietnam, 2001

Participant, International Society for Experimental Hematology Meeting, Tokyo, Japan, 2001

Participant, AIDS Vaccine 2001, Philadelphia, PA, 2001

Speaker, XXI International Symposium on Leukemia, Lymphoma, and AIDS: Pathogenesis and Treatment Padova/Venice, Italy, 2001

Invited Participant, Antigen Presenting Cells in HIV Pathogenesis and Therapy Meeting (NIH Office of AIDS Research and NCI), Warrenton, VA, 2001

Participant, 19<sup>th</sup> Annual Symposium on Nonhuman Primate Models for AIDS, San Juan, PR, 2001

Speaker, Cornell Medical Center Academic Lecture Series, New York, NY, 2001

Lecturer, University of Texas Health Science Center Lecture Series, San Antonio, TX, 2002

Invited Speaker, Post Challenge Evaluations in NHP Models, Bethesda, MD, 2002

Invited Speaker, Viral Regulatory and Accessory Genes for AIDS Vaccine Development Meeting; Bethesda, MD, 2002

Participant, 9<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002

Invited Speaker, HIV Therapies: Bench to Bedside, Palm Springs, CA, 2002

Speaker, Symposium on HIV/AIDS, Palm Springs, CA, 2002

Speaker, 3<sup>rd</sup> Workshop on Structured Treatment Interruptions, Montreal, Canada, 2002

Invited Lecturer, AIDS Clinical Trials Unit Seminar Series, Case Western Reserve University, Cleveland, OH, 2002

Doctoral Thesis Defense Committee Member, McGill University, Montreal, Canada, 2002

Invited Speaker, Cleveland HIV Immunology Symposium; Cleveland, OH, 2002

Invited Speaker, Weekly Research Meeting on Intramural HIV/AIDS Program, NIAID, Bethesda, MD, 2002

Invited Speaker, Therapeutic Vaccines against HIV and Cancers, Annecy, France, 2002

Invited Lecturer, Emory University Vaccine Center at Yerkes, Atlanta, GA, 2002

Lecturer, VII International Symposium on HTLV in Brazil, Belem, Para, Brazil, 2002

Invited Lecturer, 2002 International Meeting of the Institute of Human Virology, Baltimore, MD, 2002

Invited Lecturer, Lecture Series, Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, MD, 2002

Invited Lecturer, Aaron Diamond AIDS Research Center, New York, NY, 2002

Invited Speaker, Laboratory of Molecular Immunoregulation, NCI, Lecture Series, Frederick, MD, 2002

Invited Participant, Vaccine Research Center (NIH) Scientific Retreat, Annapolis, MD, 2002

Invited Lecturer, Vaccine Research Center (NIH) Lecture Series, Bethesda, MD, 2002

Speaker, 2002 Workshop on Pathogenesis by Non-Acute Retroviruses, Indian Wells, CA, 2002

Invited Speaker, Vaccine Research Center (NIH), Bethesda, MD, 2003

Invited Participant, Office of AIDS Research (NIH) FY 2005 HIV/AIDS Vaccine Research and Development Planning Workshop; Bethesda, MD, 2003

Speaker, HIV and Cancer Virology Faculty and Vaccine Working Group Meeting: Future Vaccines for Papilloma and AIDS Viruses, Bethesda, MD, 2003

Invited Speaker, U.S. - Japan Cooperative Medical Science Program, 15<sup>th</sup> Joint Meeting of the AIDS Panels Okinawa, Japan, 2003

Lecturer, HIV and AIDS Malignancy Branch, NCI (NIH), Bethesda, MD, 2003

Invited Speaker, Keystone Symposium on HIV Vaccine Development, Banff, Alberta, Canada, 2003

Invited Participant, HIV Therapeutic Vaccines: Moving the Field Forward, Washington, DC, 2003

Participant, Retroviruses Meeting, Cold Spring Harbor, NY, 2003

Participant, International Conference on Human Retrovirology: HTLV, San Francisco, CA, 2003

Invited Speaker, Metabolism Branch, NCI, Seminar Series, Bethesda, MD, 2003

Participant, 32<sup>nd</sup> Annual Meeting of the International Society for Experimental Hematology, Paris, France, 2003

Invited Participant, Adult AIDS Clinical Trials Group Meeting, Washington, DC, 2003

Invited Speaker, HIV & AIDS Malignancy Branch, NCI Seminar Series, Bethesda, MD, 2003

Invited Speaker, International Meeting of the Institute of Human Virology, Baltimore, MD, 2003

Invited Speaker, AIDS: Pandora's Box, Catania, Italy, 2003

Invited Participant, 2<sup>nd</sup> Annual Vaccine Research Center Scientific Training Retreat, Annapolis, MD, 2003

Invited Participant, Transatlantic Cooperation on Combating Bioterrorism Symposium, Washington, DC, 2003

Participant, 1<sup>st</sup> International Workshop on HIV Persistence during Therapy; Saint Martin, French West Indies, 2003

Invited Participant, "Assessment of Future Developments of Immune Based Therapies in HIV Infection," NIAID, Lansdowne, VA, 2004

Invited Speaker, NIAID Immune Therapy/Cytokine Symposium, Bethesda, MD, 2004

Invited Speaker, Molecular Microbiology and Immunology Department and Infectious Diseases Department Seminar Series, Johns Hopkins University, Baltimore, MD, 2004

Invited Speaker, Molecular, Cellular and Developmental Biology Seminar Series, Ohio State University, Columbus, OH, 2004

Lecturer, Trans-NIH/FDA Intramural Biodefense Symposium, NIAID, Bethesda, MD, 2004

Invited Presenter, Office of AIDS Research Advisory Council Meeting, NIH, Bethesda, MD, 2004

Participant, "Molecular Mechanisms of HIV Pathogenesis," a Keystone Symposium, Whistler, British Columbia, Canada, 2004

Invited Participant, Orthopox Research Group Meeting, NIAID, Bethesda, MD, 2004

Invited Lecturer, Therapeutic Vaccines Mini-symposium, Part of Basic Aspects of Vaccines National Symposium, Bethesda, MD, 2004

Invited Speaker, "Therapeutics in HTLV-1-Associated Neurologic Disease" Workshop, Montego Bay, Jamaica, 2004

Invited Speaker, NIAID/NIH Biodefense Clinical Research Workshop, Bethesda, MD, 2004

Invited Mini-symposium Co-chair/Speaker, 12<sup>th</sup> International Congress of Immunology/4<sup>th</sup> Annual Conference of FOCIS, Montreal, Canada, 2004

Invited Speaker, McGill University Continuing Medical Education Seminar Series, Montreal, Canada, 2004

Invited Speaker, "Animal Models for HIV Therapeutic Vaccines Meeting," Pearl River, NY, 2004

Invited Speaker/Oral Abstract Session Co-chair, AIDS Vaccine 2004, Lausanne, Switzerland, 2004

Invited Speaker, Department of Genito - Urinary Medicine & Communicable Diseases Seminar Series, Imperial College, London, UK, 2004

Speaker, International Poxvirus and Iridovirus Symposium, Oxford, UK, 2004

Invited Speaker, “Immunomodulating Drugs for the Treatment of HIV/AIDS,” Poiano/Costermano/Lake Garda, Italy, 2004

Invited Speaker, 3<sup>rd</sup> Heinrich F. C. Behr Symposium & LEOPOLDINA Conference “Microbes and Malignancy,” Heidelberg, Germany, 2004

Invited Participant, Vaccine Research Center (NIH) Scientific Training Retreat, Richmond, VA, 2004

Co-chair/Speaker, HTLV Session, International Meeting of the Institute of Human Virology, Baltimore, MD, 2004

Invited Speaker, 2<sup>nd</sup> International Symposium on Oncovirology, Salvador, Bahia, Brazil, 2004

Lecturer, Microbiology Seminar Series, University of Texas Southwestern Medical Center, Dallas, TX, 2004

Invited Speaker, 8<sup>th</sup> International Symposium on HTLV in Brazil, Sao Paulo, Brazil, 2005

Invited Participant, “Vaccines for Hepatitis-C Virus” Workshop, NIAID, Bethesda, MD, 2005

Invited Lecturer, Pathogenesis Seminar Series, Center for AIDS Research, Seattle Biomedical Research Institute, Seattle, WA, 2005

Invited Speaker, Department of Microbiology and Immunology Seminar Series, Uniformed Services University of the Health Sciences, Bethesda, MD, 2005

Invited Speaker, “HIV Vaccines: Current Challenges and Future Prospects,” a Keystone Symposium, Banff, Canada, 2005

Invited Speaker, Orthopox Research Group Fifth Annual Meeting, NIH, Bethesda, MD, 2005

Invited Speaker, NCI Immunology Faculty Seminar Series; Bethesda, MD, 2005

Invited Speaker, Biodefense Forum, Ft. Detrick, MD, 2005

Invited Speaker, NIAID Grand Rounds, Bethesda, MD, 2005

Invited Speaker, “HIV: Bridging the Sciences—Vaccine Research and Drug Development,” Atlanta, GA, 2005

Invited Speaker, 10<sup>th</sup> German and 16<sup>th</sup> Austrian HIV Conference, Vienna, Austria, 2005

Invited Speaker/Session Co-chair, “T cell Turnover and Homeostasis in HIV Infection” Workshop, Bethesda, MD, 2005

Co-organizer/Speaker, HTLV Symposium, Montego Bay, Jamaica, 2005

Co-organizer/Speaker, Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, Munich, Germany, 2005

Co-organizer, Symposium Chair, AIDS Vaccine 2005, Montreal, Canada, 2005

Participant, 23<sup>rd</sup> Annual Symposium on Nonhuman Primate Models for AIDS; Portland, OR, 2005



Invited Speaker, Emerging and Re-emerging Viral Infections and Biodefense, Rome, Italy, 2005

Co-organizer/Speaker, Dead Sea Colloquium on HIV and Cancer Vaccine Research, Amman, Jordan, 2005

Invited Speaker, Gene Therapy and Vaccines Seminar Series, University of Pennsylvania School of Medicine, Philadelphia, PA, 2006

Invited Speaker, NIAID Poxvirus Workshops, Bethesda, MD, 2006

Invited Speaker, Palm Springs Symposium on HIV/AIDS; Palm Springs, CA, 2006

Invited Speaker, HIV Research Program Seminar Series, Henry M. Jackson Foundation, Rockville, MD, 2006

Co-organizer/Speaker, "HIV Vaccines," A Keystone Symposium, Keystone, CO, 2006

Invited Speaker, International Workshop on Viral Oncology, Padova, Italy, 2006

Invited Speaker, "Infectious Basis of Cancer: Insights and Therapeutic Opportunities," Mayo Clinic, Rochester, MN, 2006

Invited Speaker, Regulatory T cells and HIV/AIDS Workshop, Cincinnati, OH, 2006

Invited Speaker, 3<sup>rd</sup> International Conference on Innovative Therapies for Lymphoid Malignancies, Palermo, Italy, 2006

Invited Speaker, 5<sup>th</sup> National Congress of the Italian Society for Infectious and Tropical Diseases, Catania, Italy, 2006

Invited Speaker, 20<sup>th</sup> National Congress on AIDS & Related Diseases, Rome, Italy, 2006

Invited Speaker, "Innate Immunity & Novel Vaccines" Symposium, Miami, FL, 2007

Invited Speaker, University of Alabama Center for AIDS Research Lecture Series, 2007

Invited Speaker, HIV Winter Symposium, Miami, FL, 2007

Speaker/Co-organizer, "Viruses, Genes and Cancer," Venice, Italy, 2007

Session Chair, 13<sup>th</sup> International Conference on Human Retrovirology, Hakone, Japan, 2007

Invited Speaker, "Translating Basic HIV Immunology in Novel Interventions" Workshop, Sydney, Australia, 2007

Invited Speaker, 13<sup>th</sup> International Conference of Immunology; Rio De Janeiro, Brazil, 2007

Invited Speaker, "Challenges in HIV Vaccines" Satellite Symposium, Rio De Janeiro, Brazil, 2007

Invited Speaker, "HIV/AIDS Research at the NCI: a Record of Sustained Excellence," Bethesda, MD, 2007

Invited speaker, Rush University, Chicago, "CTLA-4 Blockade in SIV Infection," 2008

Invited speaker, "Negative Regulatory Cells in HIV/SIV Infection" Symposium, Palm Springs, CA, 2008

Chairperson and Speaker, Keystone Meeting on HIV Vaccine and Pathogenesis, Banff, Canada, 2008

Participant, Cold Spring Harbor, NY, 2008

Invited Speaker, X Simposio Internacional Sobre HTLV NO BRASIL, "Novel Functional insights on the HTLV-1 P13 II and P12 I Proteins" Rio de Janeiro, Brazil, 2008

Invited Speaker, 3o Simposio sobre avanos na patogonia e manejo da AIDS, "The immune response and factors that affects HTLV-1 genetic regulation: prospects for HIV vaccine" Bahia, Brazil, 2008

Invited Speaker, Journal of Medicine and The Royal Swedish Academy of Sciences' 5<sup>th</sup> Key Symposium Mucosal Immunity and Novel HIV-vaccine Concepts, "Can we use monkeys for human HIV vaccine models?" Stockholm, Sweden, 2008

Organizer, Vaccine Branch Fall HIV/AIDS and Cancer Think Tank Meeting, NIH, Bethesda, MD, 2008

Invited Speaker/Participant, The Cleveland Immunopathogenesis Consortium, "Defining the Pathogenesis of Immune Deficiency in Chronic HIV Infection" Cleveland, OH, 2008

Chairperson, Special Emphasis Panel/Scientific Review Group 2009/01 VACC meeting, Study Session, 2008

Invited Speaker/Participant, 50th ASH Annual Meeting, San Francisco, CA, 2008

Participant, 2009 NCI Intramural Scientific Investigators Retreat, Bethesda, MD, 2009

Participant/Invited Guest, "25 Years after Discovering HIV as the Cause of AIDS." Symposium honoring Dr. Robert C. Gallo, Baltimore, MD, 2009

Invited Speaker/Participant, 14th International Conference on Human Retrovirology: HTLV and Related Retroviruses, Salvador Bahia, Brazil, 2009

Participant, 21st Retroviral Pathogenesis Conference, Lucca, Italy, 2009

Organizer, Vaccine Branch Fall HIV/AIDS and Cancer Think Tank Meeting. NIH, Bethesda, MD, 2009

Invited Speaker, DIADS/HVTN Seminar Series, NIH, Bethesda, MD, 2010

Invited Speaker, EIB seminar schedule, 2010

Invited Speaker, University of Padova, Italy, 2010

Invited Speaker, University of Naples, Italy, 2010

Invited Speaker, Palm Springs Symposium on HIV/AIDS, Palm Springs, CA, 2010

Invited Speaker, Cleveland Immunopathogenesis Consortium, Cleveland, OH, 2010

Invited Speaker, Rush Medical Center, Chicago, IL, 2010

Invited Speaker, Immune Activation in HIV Pathogenesis Models and Targets Meeting, Potomac, MD, 2010

Invited Participant, Army-US Military HIV Research Program Scientific Retreat Williamsburg, VA, 2010

Invited Speaker, Cold Spring Harbor, NY, 2010

Invited Speaker, New Insights Into Mucosal Transmission of HIV/SIV and Its Prevention by Vaccines and Other Modalities Meeting, Bethesda, MD, 2010

Invited Speaker, FOCIS 10<sup>th</sup> Annual Meeting, Boston, MA, 2010

Invited Speaker, IHV Meeting, Venice, Italy, 2010

Co-Organizer; Virus, Genes and Cancer Meeting, Venice, Italy, 2010

Invited Speaker, 12th Annual International Meeting of the Institute of Human Virology of the University of Maryland School of Medicine, Calabria, Italy, 2010

Organizer, Vaccine Branch Fall HIV/AIDS and Cancer Think Tank Meeting, NIH, Bethesda, MD, 2010

Invited Speaker, University of Maryland, Baltimore, MD, 2010

Participant, RV144 Meeting and Correlates of Protection Workshop, Seattle, WA, 2010

Invited Speaker, Keystone Symposium, Mucosal Biology: A Fine Balance between Tolerance and Immunity, Vancouver, Canada, 2011

Invited Speaker, Kyoto Symposium, Kyoto Japan, 2011

Invited Participant, AMEH Annual Meeting, Cancun Mexico, 2011

Invited Participant, Ruprecht Lab Annual Clade C Program Project Meeting, 2011

Chairperson, HTLV-I Meeting, Leuven, Belgium, 2011

Invited Speaker, Internal Medicine of Medical University of Bialystok, Poland, 2011

Invited Speaker, VGTI, Vaccine and Gene Therapy Institute, Port St. Lucie, FL, 2011

Invited Speaker, SIMPAIDS, Bahia, Brazil, 2011

Invited Speaker, Workshop on HTLV-I and HIV-1 Databases, Bahia, Brazil, 2011

Invited Speaker, AIDS Vaccine Meeting, Bangkok, Thailand, 2011

Invited Speaker, XXV IACRLRD Symposium Tokyo, Japan, 2011

Invited Speaker, Annual Non-Human Primate AIDS Meeting, Seattle, WA, 2011

Invited Speaker, Robert Gallo's Laboratory, Baltimore, MD, 2011

Organizer, Vaccine Branch Fall HIV/AIDS and Cancer Think Tank Meeting, NIH, Bethesda, MD; 2011

Invited Speaker, Advance Topic Lecture, Memorial Sloan-Kettering Cancer Center, New York, NY, 2011

Invited Speaker, 1º Congresso Brasileiro de HIV/AIDS e virus relacionados, Bahia, Brazil, 2011

Invited Speaker, 2012 Palm Springs Symposium on HIV/AIDS, Palm Springs, CA, 2012

Abstract Reviewer, AIDS 2012 Meeting, Bethesda, MD, 2012

Invited Speaker, HIV Cells of Macrophage/Dendritic Lineage and other Reservoirs, Stresa, Italy, 2012

Invited Speaker, AIDS 2012 Vaccine Meeting, Boston, MA, 2012

Invited Speaker, IHV Meeting, Baltimore, MD, 2012

Co-Organizer; Virus, Genes, and Cancer Meeting, Venice, Italy, 2012

Organizer, Vaccine Branch Fall HIV/AIDS and Cancer Think Tank Meeting, NIH, Bethesda, MD; 2012

Invited Speaker, Keystone, Keystone, CO, 2013

Invited Speaker, GeoVax Advisory Board Meeting, Atlanta, GA 2013

Invited Speaker, HIVRAD-SAB Meeting Emory University, Atlanta, GA, 2013

Invited Speaker, HTLV-I Annual Meeting, Montreal, Canada; 2013

Invited Speaker, HU Annual SAB meeting; Seattle, WA 2013

Co-Chair, Stadtman Virology Search, Bethesda, MD, 2014

Invited Speaker, NIAID, Lecture, Bethesda, MD, 2014

Invited Speaker, Palm Springs, HIV Infection: Towards a Cure, 2014

Invited Speaker, Keystone Banff Spring, Canada, 2014

Invited Participant, CDC, Poxvirus Program Review Panel, Atlanta, GA, 2014

Invited Speaker, AIDS Vaccine Research Subcommittee (AVRS), Washington, DC, 2014

Invited Board Member, HU VDC SAB Meeting, Seattle, WA, 2014

Participant, IVH Annual Meeting, Baltimore, MD, 2014

Invited Speaker, Cent Gardes Conference HIV Vaccines, 2014

Invited Speaker, 32<sup>nd</sup> Symposium on Non-human primate models for AIDS, Portland, OR, 2014

Invited Speaker, 3rd Conference on Translational Medicine on Pathogenesis and Therapy of Immune-Mediated Diseases, Milan, Italy, 2014

Invited Speaker, 2014 ISSNAF Annual Event - Young ISSNAF Career Symposium, Washington, DC, 2014

Invited Speaker, Kunming Institute of Zoology/Kunming Primate Research Center, Kunming, Yunnan, China, 2014

Organizer, Vaccine Branch Fall HIV/AIDS and Cancer Think Tank Meeting, NIH, Bethesda, MD, 2014

Invited Speaker, Yerkes National Primate Research Center, Emory University School of Medicine, 2014

Invited Speaker, 2014 Palm Springs Symposium on HIV/AIDS, 2014

Invited Speaker, HIV R4P, Cape Town International Convention Center, Cape Town, South Africa, 2014

Invited Speaker, Cent Gardes Conference on HIV Vaccines, Les Pensieres Conference Center Veyrier du Lac, Annecy, France, 2014

Invited Speaker, Italian Society of Immunology, Clinical Immunology and Allergology, Milan, Italy, 2014

Invited Member, Scientific Advisory Board (SAB) meeting, Seattle, WA, 2014

Participant, HIV Vaccine - Keystone Symposia, Banff, Alberta, Canada, 2014

Invited Speaker, 2015 Keystone Symposia on Viruses and Human Cancer, Big Sky, MT, 2015

Invited Speaker, Rush University Medical Center, Chicago, IL, 2015

Invited Speaker, 17<sup>th</sup> International Conference on Human Retrovirology: HTLV & Related Viruses, Trois-Ilets, Martinique, France, 2015

Speaker, HIV Vaccine - Keystone Symposia, Banff, Alberta, Canada, 2015

Invited Member, VDC SAB Meeting, Seattle, WA 2015

Invited Speaker, Cancer: Inflammation and Immunity, Network Italiano per la Bioterapia dei Tumori, Finalborgo, Italy, 2015

Invited Speaker, XXVII International Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, Paris, France, 2015

Invited Speaker, 2015 Workshop on Tumor Viruses, University of Padua, Padua, Italy, 2015

Invited Speaker, 17th Annual International Meeting, Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, MD, 2015

Invited Speaker, Cleveland Immunopathogenesis Consortium, BBC, Case Western, Cleveland, OH, 2015

Award Recipient, Center for Retrovirus Research Distinguished Research Career Award, Center for Retrovirus Research of The Ohio State University, Columbus Ohio, 2016

Invited Member, SAB Emory, Atlanta, GA, 2015

Participant, RAS Initiative Symposium, Frederick, MD, 2015

Invited Speaker, U.S. – Japan Cooperative Medical Sciences Program AIDS Panel Meeting, Bethesda, MD, 2016

Invited Speaker, Keystone Symposium on HIV Vaccines, Olympic Valley, California, 2016

Speaker, HERN Conference, Romania, 2016

Invited Speaker, IARC Meeting – Emerging Issues in Oncogenic Virus Research, Manduria, Italy, 2016

Patent Material >\$8M in royalties to date (to NIH):

Patent 5223423: "Characterization of Replication Competent Human Immunodeficiency Type 2 Proviral Clone." Issued 6/29/93.

Patents 5420030, 5576000, 5869313: "Molecular Clones of HIV-1 viral strains MN-ST1 and BA-L and uses thereof." Issued 5/30/95, 11/19/96, 2/9/99, respectively.

Patent 5833975: "Recombinant Poxvirus-HTLV, Compositions and Uses." Issued 11/10/98.

Patent 5766598: ARecombinant Attenuated ALVAC Canarypoxvirus Expression Vectors Containing Heterologous DNA Segments Encoding Lentiviral Gene. Issued 6/16/98.

Patent 5863542: AImmunodeficiency Recombinant Poxvirus. Issued 1/26/99.

Patent 7094408: AImproved Immunogenicity Using a Combination of DNA and Vaccinia Virus Vector Vaccines. U.S. Issued 8/22/06.

Patent application 10/495532: ANovel Chimeric Rev, Tat, and Nef Antigens. DHHS E-158-2000/0-US-03.

U.S. Provisional Patent Application No. 60/404,580 filed 19 Aug 2002 (DHHS Reference No. E-173-2001/0-US-01); PCT Application No. PCT/US03/25958 filed 19 Aug 2003 (DHHS Reference No. E-173-2001/0-PCT-02): "HTLV-1 p30II and p12I Proteins as Therapeutic Targets in HTLV-1 Infected Individuals."

Patent application PCT/US03/35499: "Smallpox Vaccine Regimen." DHHS E-249-2002/0-PCT-1. Also known as Patent application 60/559,906; DHHS E-138-2004/0-US-01.

Patent application 10/048,072 filed 25 January 2002 (DHHS Reference No. E-212-1999/2-PCT-06) SLW Reference No. 1662.018US1 "Immunotherapy in HIV Infected Persons Using Vaccines After Multi-Drug Treatment."

Patent application 10/513257: "Immunotherapy Regimens in HIV-Infected Patients." DHHS E-128-2002/0-US-03. Docket 1662.013US1. Also known as Patent application 10/048,072; DHHS E-212-1999/2-PCT-06.

U.S. Patent Application No. 11/364873 filed 27 Feb 2006: "HIV Tev Compositions and Methods of Use."

U.S. Patent Application No. 61/081,994, filed 18 July 2008: "HTLV-II Vector and Methods of Use."

U.S. Patent Application No. 11/523,867, filed 20 September 2006: "DNA vaccines against poxvirus."

U.S. Patent Application No. 61/447,499, filed 28 February 2011: "Cervicovaginal vaccination with papillomavirus pseudovirions for protection against mucosotropic infections"

U.S. Patent Application No. E-055-2013/0 Filed 2013 "Combined Cell Based Gp96-ig-siv/hiv, Recombinant Gp120 Protein Vaccination For Protection From Siv/hiv". Patent pending; PCT/US2012/026256 (PC application).

Employee Invention Report: "A Method to Develop B cell Epitope-Based Effective Vaccine Modalities for Smallpox for Both Immune-Competent and Immune-Compromised Individuals."

Employee Invention Report: "An Alternatively Spliced Tat V1 Rev Protein (Tev) Product as a Component of an HIV Vaccine."

US Patent Application No, 61925154: RAS pathways as marker of protection against HIV and means to improved vaccine efficacy, filed 8 January 2015

Licenses: FY 2014

Vertex Pharmaceuticals Incorporated

E-143-1989/1 titled "HIV Chronically Infected Human T Cell Clone",  
E-062-1990/0 titled "Molecular Clones of HIV 1 and Uses Thereof",  
B-003-1998/0 titled "HIV-1p24 Monoclonal Antibody (183-H12-5C)",  
B-005-1999/0 titled "Novel Infectious Clones of HIV DNA for Easy Mutational Changes",  
B-026-1999/0 titled "CEM-SS HIV susceptible Cell Line NIH AIDS Reference Reagent #776", and  
E-172-2002/0 titled "Cytokine-Induced Expression of HIV-1 in a Chronically Infected Promonocyte Cell Line".

Immune Design Corporation

E-041-2011/1 titled "C8166-45 Cell Line".

Competitive Funding:

Competitive supplemental funding FY 2000:

\$20,000 to organize an HTLV-I conference

\$300,000: NYVAC-SIV vaccine combined with immunomodulatory molecule after HAART failure.

Collaborative Project Award II: \$414,721: Ability of intrarectal administration of multi-epitope synthetic peptide HIV/SIV vaccine to induce mucosal T-cell immunity and protection against mucosal transmission of SHIV. PI #1: Genoveffa Franchini (NCI). PI #2: Jay A. Berzofsky (NCI).

Bench-to-Bedside Award: \$210,000. PI (basic science): Genoveffa Franchini (NCI). PI (clinical investigator): Ashish Jain (NIAID).

OAR Discretionary Funds (FY 2000): \$440,000. Phase I clinical trial with NYVAC HIV as immunotherapy in HIV-I-infected individuals treated with HAART. Investigators: Genoveffa Franchini (NCI), Gene Shearer (NCI), Robert Yarchoan (NCI).

IATAP (FY 2002): \$250,000. Investigators: Genoveffa Franchini, Marjorie Robert-Guroff, Carl C. Baker (all NCI).

NIAID Intramural Biodefense Research Award: \$997,100: Prevention and treatment of complications of smallpox vaccination in a macaque model of acquired immunodeficiency. Investigators: Genoveffa Franchini (NCI), Mike Bray (NIAID), Hana Golding (FDA), Dorothy Scott (FDA).

Competitive supplemental funding FY 2005: \$15,000 to organize an HTLV-1 conference.

NIH/NIAID 1R21 AI073234-01; 3/15/07-02/28/09; \$150,000: Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96. Evaluate gp96-vaccines for SIV and study the optimal dose of SIV gp-96 vaccines for induction of systemic and mucosal immunity. PI: E. Podack (University of Miami).

NIH/NIAID 1R21 AI073234-01; 3/15/07-02/28/09; \$150,000: Induction of mucosal SIV immunity in non human primates by secreted Hsp-Gp96. Evaluate gp96-vaccines for SIV and study the optimal dose of SIV gp-96 vaccines for induction of systemic and mucosal immunity. PI: E. Podack (University of Miami).

Competitive supplemental funding FY 2009:

\$25,000 to organize an HTLV-I Conference

OAR Awarded: \$145,000. PI #1: Genoveffa Franchini (NCI) PI #2 Chris Buck (NCI), PI #3 John Schiller (NCI).

HPV Pseudovirus vaccine against mucosal HIV/SIV transmission 2010

OAR/NCI Awarded: \$1,500,000, FY 2010/2011. PI #1: Genoveffa Franchini (NCI). Dissection of the immune correlates of HIV vaccine protection in the macaque model

(NCI)RRS: Awarded 196,00.00.FY 2014.Genoveffa Franchini (NCI). Testing the effect of IGF-1 and RAS activation in vaccine protection against HIV/SIV

Reviewer For:

AIDS; AIDS Research and Human Retroviruses; AIDS Reviews; American Journal of Pathology; Annals of Neurology; Antiviral Chemistry and Chemotherapy; Blood; Cancer Genetics and Cytogenetics; Cancer Research; Carcinogenesis; Cell Immunology; Cellular and Molecular Life Sciences; Clinical and Diagnostic Laboratory Immunology; Clinical Infectious Diseases; DNA and Cell Biology; European Journal of Immunology; FEBS Letters; Immunogenetics; Immunology Letters; International Journal of Cancer; Journal of Acquired Immune Deficiency Syndromes; Journal of AIDS and Human Retrovirology; Journal of AIDS Research; Journal of Biological Chemistry; Journal of Clinical Investigation; Journal of Experimental Medicine; Journal of General Virology; Journal of Human Virology; Journal of Immunological Methods; Journal of Immunology; Journal of Infectious Diseases; Journal of Investigative Dermatology; Journal of Leukocyte Biology; Journal of the National Cancer Institute; Journal of Virology; Leukemia; Leukemia Research; Molecular and Cellular Biology; Molecular Biology of the Cell; Molecular Therapy; Molecular Pharmacology; Mucosal Immunology; National Cancer Institute Monographs; Nature Medicine; Nature Reviews Immunology; Oncogene; PLoS Pathogens; Proceedings of the National Academy of Sciences of the United States of America; Science; Vaccine; Viral Immunology; Virology; World AIDS Conference Abstracts

Committees and Programs:

HIV Drug Resistance Program Search Committee, NCI  
Tenure Track and Search Committees, NIAID  
Tenure Track Committee, HIV and AIDS Malignancies Branch, NCI  
Ph.D. Dissertation Examiner, Microbiology and Tumorbiology Center of the Karolinska Institute  
Howard Hughes Medical Institute-NIH Research Scholars Program  
Senior Scientist Search Committee, Laboratory of Genomic Diversity, NCI  
Italian University Grants System Program  
AIDS and Related Research Study Section 1, Molecular and Cellular Biology of HIV and Related Viruses, NIAID  
Dana-Farber Cancer Institute External Advisory Board: Vaccination against Intrapartum HIV Clade C Transmission  
Intramural Advisory Board, NCI  
Office of AIDS Research Coordinating Committee on Vaccine Research, NCI  
Ad Hoc Subcommittee on Vaccinia Immunization, NIH  
Promotion and Tenure Review Panel, DCEG, NCI  
Board of Scientific Counselors, NIAID  
Tenure-Track Search Committee, Hematology Branch, NHLBI  
Office of AIDS Research HIV Vaccine Research & Development Planning Workshops, NIH  
Intramural AIDS Targeted Antiviral Program application-review committee, NIH  
Special Emphasis Panel, "HIV Research and Design," NIAID Scientific Review Program  
HIV and Cancer Virology Faculty, NCI  
Vaccine Working Group, NCI  
Attenuated Vaccinia Interagency Working Group  
Scientific Review Program, Division of Extramural Activities, NIAID  
NIH Academy Preceptor  
HTLV Advisory Group, NCI  
AIDS Vaccine Research Working Group, NIH  
HIV/AIDS Vaccine Study Section, Center for Scientific Research, NIH; chair  
Recombinant DNA Advisory Committee, Office of Biotechnology Activities, NIH  
Animal Research Advisory Committee, NIH  
Tenure/Tenure-Track Search Committee, Laboratory of Molecular Microbiology, NIAID; chair



Medical Research Council, Triage, Infections and Immunity Board, grant proposal reviewer  
 New York Academy of Medicine, preceptor  
 American Academy of Allergy Asthma & Immunology Summer Fellowship Program, preceptor  
 Infectious Disease Society of American fellowship program, preceptor  
 NIH/Johns Hopkins University graduate program, thesis committee member  
 HIV & AIDS Malignancy Branch, NCI, Viral Oncogenesis Principal Investigator Recruitment Committee; Chair  
 Steering Committee, Center of Excellence in HIV/AIDS and Cancer Virology, NCI; cochair  
 Integrated Preclinical/Clinical AIDS Vaccine Development Program peer review, NIAID  
 International Association for Comparative Research on Leukemia and Related Diseases, Committee member  
 External Scientific Advisory Board, HIVRAD, Emory Vaccine Center, Yerkes National Primate Research Center  
 External Advisory Board of the GeoVax Vaccine Development, Smyrna Georgia

Mentorship: Former Laboratory Members and Current Affiliations:

Aldovini, Anna	Associate Professor of Pediatrics, Children's Hospital, Boston, Mass
Ali, Mir	Technician, NCI
Alonzo, Norma C.	Patent Advisor, U.S. Patent and Trademark Office
Ballotta, Claudia	Associate Professor, Scientific Institute San Raffaele, Milan, Italy
Berneman, Zwi	Professor of Hematology; Head of the Laboratory of Experimental Hematology, University of Antwerp. Chief, Division of Hematology, Antwerp University Hospital
Boeri, Enzo	Researcher, Scientific Institute San Raffaele, Milan, Italy
Casareto, Luca	Bioinformatics Specialist, Informax, Inc.
Cereseto, Anna	Professor, University of Trento, Italy
Di Giglio, Laura	Researcher, Merck
Dundr, Miroslav	Assistant Professor, Rosalind Franklin University of Medicine & Science
Edghill-Smith, Yvette	Program assistant, Leader, NIAID
Ferrari, Maria Grazia	Staff Scientist, Advanced BioScience Laboratories, Inc.
Fu, Kaisong	Clinical medicine
Gessain, Antoine	Director, Oncogenic Virus Epidemiology and Pathophysiology, Institut Pasteur, France
Giri, Adriani A.	Associate Professor, Universidad Nacional de Rosario, Argentina
Giuliani, Laura	Assistant Professor, University of Rome, Italy
Harrod, Robert L.	Associate Professor, Southern Methodist University
Hel, Zdenek	Associate Professor, University of Alabama
Hryniewicz, Anna	Professor, Medical University, Bialystok, Poland
Johnson, Julie M.	Research Scientist, Martek Biosciences
Kislyakova, Tatiana	Assistant Professor, Russian Academy of Sciences, Russia
Koralnik, Igor J.	Associate Professor; Director, HIV/Neurology Center, Beth Israel Deaconess Medical Center
Marcon, Luisa	Researcher, University of Rome, Italy; Assistant Professor, Brown Medical School
Moniuszko, Marcin	Chief, Department of Regenerative Medicine and Immune Regulation Medical University of Bialystok, Poland
Mulloy, James C.	Associate Professor, Cincinnati Children's Hospital Medical Center
Nacsa, Janos	
Nicot, Christophe	Full Professor, University of Kansas
Rivadeneira, Emilia	Physician, Mt. Sinai Medical Center
Silic-Benussi, Micol	Research scientist, University of Padova, Italy
Stevceva, Liljana	Medical Officer, NIAID
Takemoto, Shigeki	Physician, Kochi Medical School, Japan
Trindade, Christopher	Senior Medical Scientist for Gilead M. D.
Trovato, Raffaella	Researcher, Policlinico di Modena, Department of Medical Sciences, Italy
Ferrari M. Grazia	Senior Scientist, ABL, Inc, Rockville MD
Tryniszewska, Elzbieta	Full Professor, Physician, Medical Academy of Bialystok, Poland
Cecchinato Valentina	Researcher, Bellinzona, Switzerland

Jean- Michel Heraud	Director of the Laboratorie Natcional OMS Institute Pasteur de Madagascar
Fukumoto Risaku	Researcher, Navy Medical University (Bethesda MD)
Valerio Valeri	University of Firenze /Corporate Affiliation, Italy
Shari Gordon	Senior Scientist, GSK, North Carolina, USA
Poonam Pegu	Postdoc, Military HIV Research Program (MHRP)
Heather Gold	Tulane Medical School
Claudio Fenizia	Second Postdoc Epigenetic of Muscle Mass, Department of Bioscience, University of Milan
Martina Focchi	Second postdoc at the San Raffaele institute (HSR)
Nancy Van Prooyen	Researcher, Department of Microbiology and Immunology
Cynthia P. Masison	Scientific Program Analyst, Office of Scientific Programs, OD/CCR/NCI
Dustin Edwards	Assistant Professor, Department of Biological Sciences College of Science and Technology Tarleton State University, Stephenville, TX
Adriano Boasso	Research Fellow, Faculty of Medicine, Department of Medicine, Imperial College, London.
Izabela Bialuk	Researcher, Medical University of Bialystok, Department of General and Experimental Pathology
Luiz Carlos Alcantara	Researcher, Fundação Oswaldo Cruz, Centro de Pesquisas Gonçalo Moniz, Fiocruz, Brazil

## BIBLIOGRAPHY

1. Torelli, U., Torelli, G., Cadossi, R., Ferrari, St., Ferrari, Se., Montagna, G., Narni, F., Franchini, G., and Donelli, A.: The primary product of DNA transcription in the blast cell of acute leukemia. Its characterization as an approach to the understanding of the origin of the blast crisis of chronic myeloid leukemia. *Boll. Inst. Sieroter. Milanese* 1978 57:325-333.
2. Torelli, G., Narni, F., Franchini, G., Donelli, A., Ferrari, S., Calabretta, B., Torelli, U., and Bosi, P.: Kinetics of hybridization to human DNA of heterogenous nuclear RNA isolated from normal human lymphoblasts and acute leukemic blast cells. *Mol. Biol. Rpt.* 1979 51:181-184.
3. Torelli, U., Donelli, A., Franchini, G., Calabretta, B., Ferrari, S., Narni, F., Torelli, G., Bagnara, G.P., and Brunelli, M.A.: Characteristics of macromolecular RNA metabolism in leukemic premyelocytes of the HL-60 line. *IRCS Med. Sci.* 1980 8:443.
4. Wong-Staal, F., Franchini, G., and Gallo, R.C.: Some studies on the nature and expression of viral genetic information in cells from normal and leukemic cats. In Hardy, W.D., Essex, M., and McClelland, A.J. (Eds.): *Feline Leukemia Virus*. New York, Elsevier North-Holland Press, 1980, pp. 381-391.
5. Franchini, G., Even, J., Sherr, C.J., and Wong-Staal, F.: Onc sequences (v-fes) of Snyder-Theilen feline sarcoma virus are derived from noncontiguous regions of a cat cellular gene (c-fes). *Nature* 1981 290:154-157.
6. Wong-Staal, F., Dalla Favera, R., Franchini, G., Gelmann, E.P., and Gallo, R.C.: Three distinct genes in human DNA related to the transforming genes of mammalian sarcoma retroviruses. *Science* 1981 213:226-228.
7. Franchini, G., Gelmann, E.P., Dalla Favera, R., Gallo, R.C., and Wong-Staal, F.: Human gene (c-fes) related to the onc sequences of Snyder-Theilen sarcoma virus. *Mol. Cell. Biol.* 1982 2:1014-1019.
8. Dalla Favera, R., Franchini, G., Martinotti, S., Wong-Staal, F., Gallo, R.C., and Croce, C.: Chromosomal assignment of the human homologues of feline sarcoma virus and avian myeloblastosis virus onc genes. *Proc. Natl. Acad. Sci. USA* 1982 79:4714-4717.
9. Dalla Favera, R., Gelmann, E.P., Martinotti, S., Franchini, G., Papas, T.S., Gallo, R.C., and Wong-Staal, F.: Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29). *Proc. Natl. Acad. Sci. USA* 1982 79:6497-6501.
10. Manzari, V., Gallo, R.C., Franchini, G., Westin, E., Ceccherini-Nelli, L., Popovic, M., and Wong-Staal, F.: Abundant

transcription of a cellular gene in T cells infected with human T-cell leukemia-lymphoma virus. *Proc. Natl. Acad. Sci. USA* 1983 80:11-15.

11. Manzari, V., Wong-Staal, F., Franchini, G., Colombini, S., Gelmann, E.P., Oroszlan, S., Staal, S., and Gallo, R.C.: Human T-cell leukemia-lymphoma virus (HTLV): Cloning of an integrated defective provirus and flanking cellular sequences. *Proc. Natl. Acad. Sci. USA* 1983 80:1574-1578.
12. Wong-Staal, F., Hahn, B., Manzari, V., Colombini, S., Franchini, G., Gelmann, E.P., and Gallo, R.C.: A survey of human leukemias for sequences of a human retrovirus. *Nature* 1983 302:626-628.
13. Haynes, B.F., Robert-Guroff, M., Metzgar, R.S., Franchini, G., Kalyanaraman, V.S., Palker, T.J., and Gallo, R.C.: Monoclonal antibody against human T-cell leukemia virus p19 defines a human thymic epithelial antigen acquired during ontogeny. *J. Exp. Med.* 1983 157:907-910.
14. Salahuddin, S.Z., Markham, P.D., Wong-Staal, F., Franchini, G., Kalyanaraman, V.S., and Gallo, R.C.: Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. *Virology* 1983 129:51-64.
15. Harper, M.E., Franchini, G., Love, J., Simon, M.I., Gallo, R.C., and Wong-Staal, F.: Chromosomal sublocalization of human c-myc and c-fes cellular onc genes. *Nature* 1983 304:169-171.
16. Wong-Staal, F., Westin, E., Franchini, G., Gelmann, E., Dalla Favera, R., Manzari, V., and Gallo, R.C.: The cloning and analyses of human cellular genes homologous to retroviral onc genes. In Chandra, P. (Ed.): *Biochemical and Biological Markers of Neoplastic Transformation*. New York, Plenum Press, 1983, pp. 479-792.
17. Franchini, G., Wong-Staal, F., Baluda, M.A., Lengel, C., and Tronick, S.R.: Structural organization and expression of human DNA sequences related to the transforming gene of avian myeloblastosis virus. *Proc. Natl. Acad. Sci. USA* 1983 80:7385-7389.
18. Wong-Staal, F., Josephs, S., Dalla Favera, R., Westin, E., Gelmann, E., Franchini, G., and Gallo, R.C.: Cellular onc genes: Their role as progenitors of viral onc genes and their expression in human cells. In Neth, R., Gallo, R.C., Greaves, M.F., Moore, M.A.S., and Winkler, K. (Eds.): *Haematology and Blood Transfusion*, Vol. 28. Berlin, Springer-Verlag, 1983, pp. 178-185.
19. Hahn, B., Manzari, V., Colombini, S., Franchini, G., Gallo, R.C., and Wong-Staal, F.: Common site of integration of HTLV in cells of three patients with mature T-cell leukaemia-lymphoma. *Nature* 1983 303:253-256.
20. Franchini, G. and Wong-Staal, F.: Retrovirus and retroviral onc genes: Possible role in human neoplasias and aplasias. In Young, N.S., Levine, A., and Humphries, R.K. (Eds.): *Aplastic Anemia: Stem Cell Biology and Advances in Treatment*. New York, Alan R. Liss, 1984, pp. 153-160.
21. Gelmann, E.P., Franchini, G., Manzari, V., Wong-Staal, F., and Gallo, R.C.: Molecular cloning of a unique human T-cell leukemia virus HTLV-II<sub>Mo</sub>. *Proc. Natl. Acad. Sci. USA* 1984 81:993-997.
22. Franchini, G., Wong-Staal, F., and Gallo, R.C.: Molecular studies of human T-cell leukemia virus and adult T-cell leukemia. *J. Invest. Dermatol.* 1984 83:63s-66s.
23. Blatt, C., Harper, M.E., Franchini, G., Nessirt, M.N., and Simon, M.I.: Chromosomal mapping of murine c-fes and c-src genes. *Mol. Cell. Biol.* 1984 4:978-981.
24. Hahn, B., Gallo, R.C., Franchini, G., Popovic, M., Aoki, T., Salahuddin, S.Z., Markham, P.D., and Wong-Staal, F.: Clonal selection of human T-cell leukemia virus-infected cells *in vivo* and *in vitro*. *Mol. Biol. Med.* 1984 2:29-36.
25. Mann, D.L., Clark, J., Clarke, M., Reitz, M., Popovic, M., Franchini, G., Trainor, C.D., Strong, D.M., Blattner, W.A., and Gallo, R.C.: Identification of the human T cell lymphoma virus in B cell lines established from patients with adult T cell leukemia. *J. Clin. Invest.* 1984 74:56-62.
26. Franchini, G., Wong-Staal, F., and Gallo, R.C.: Human T-cell leukemia virus (HTLV-I) transcripts in fresh and cultured cells of patients with adult T-cell leukemia. *Proc. Natl. Acad. Sci. USA* 1984 81:6207-6211.
27. Rowley, J.D., Haren, J.M., Wong-Staal, F., Franchini, G., Gallo, R.C., and Blattner, W.A.: Chromosome pattern in cells from patients positive for human T cell leukemia/lymphoma virus. In Gallo, R.C., Essex, M., and Gross, L. (Eds.): *Human T-Cell Leukemia/Lymphoma Viruses*. New York, Cold Spring Harbor Laboratory Press, 1984, pp. 85-89.
28. Wong-Staal, F., Franchini, G., Hahn, B., Arya, S.K., Gelmann, E.P., Manzari, V., and Gallo, R.C.: Human T-cell leukemia/lymphoma virus, *in vitro* transformation, and leukemia: Some molecular studies. In Gallo, R.C., Essex, M., and Gross, L. (Eds.): *Human T Cell Leukemia/Lymphoma Virus*. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1984, pp. 133-139.
29. Mullins, J.I., Rubsamen, H., Franchini, G., Wong-Staal, F., and Gallo, R.C.: HTLV-I<sub>UK</sub>: Molecular cloning and analysis of proviral and flanking-sequence DNA from a cell line derived from a patient with peripheral T-cell lymphoma. In Gallo, R.C., Essex, M., and Gross, L. (Eds.): *Human T Cell Leukemia/Lymphoma Virus*. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1984, pp. 157-166.
30. Gelmann, E.P., Franchini, G., Manzari, V., Wong-Staal, F., and Gallo, R.C.: Molecular cloning of a new unique

- human T cell leukemia virus (HTLV-II<sub>Mo</sub>). In Gallo, R.C., Essex, M., and Gross, L. (Eds.): *Human T Cell Leukemia/Lymphoma Virus*. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1984, pp. 189-195.
31. Wong-Staal, F., Franchini, G., Hahn, B., Arya, S., Gelmann, E.P., Manzari, V., Popovic, M., Aoki, T., and Gallo, R.C.: Molecular studies of HTLV, leukemia and in vitro transformation. In Aoki, T., Tsubura, E., and Urushizaki, I. (Eds.): *Manipulation of Host Defence Mechanisms*. Hong Kong, Excerpta Medica, 1984, pp. 162-168.
  32. Wong-Staal, F., Franchini, G., Hahn, B., Arya, S., Gelmann, E.P., Manzari, V., and Gallo, R.C.: Molecular biology of HTLV. In Aaronson, S.A., Frati, L., and Verna, R. (Eds.): *Genetic and Phenotypic Markers of Tumors*. New York, Plenum Publishing, 1985, pp. 337-344.
  33. Franchini, G. and Gallo, R.C.: Viruses, onc genes and leukemia. In Hoffbrand, A.V. (Ed.): *Recent Advances in Haematology*, Vol. 4. London, Churchill Livingstone, 1985, pp. 221-237.
  34. Gallo, R.C., Westin, E.H., and Franchini, G.: Retroviruses and onc genes in human leukemia and lymphoma. *Adv. Biosciences* 1985 50:11-19.
  35. Franchini, G., Mann, D.L., Popovic, M., Zicht, R.R., Gallo, R.C., and Wong-Staal, F.: HTLV-I infection of T and B cells of a patient with adult T cell leukemia-lymphoma (ATLL) and transmission of HTLV-I from B cells to normal T cells. *Leuk. Res.* 1985 9:1305-1314.
  36. De Rossi, A., Aldovini, A., Franchini, G., Mann, D., Gallo, R.C., and Wong-Staal, F.: Clonal selection of T lymphocytes infected by cell free human T cell leukemia/ lymphoma virus type 1: Parameters of virus integration and expression. *Virology* 1985 143:640-645.
  37. Sodroski, J.G., Goh, W.C., Rosen, C.A., Salahuddin, S.Z., Aldovini, A., Franchini, G., Wong-Staal, F., Gallo, R.C., Sugamura, K., Hinuma, Y., and Haseltine, W.A.: Trans-activation of the human T-cell leukemia virus long terminal repeat correlates with expression of the x-lor protein. *J. Virol.* 1985 55:831-835.
  38. Wong-Staal, F., Franchini, G., Hahn, B., Arya, S., Gelmann, E.P., Manzari, V., and Gallo, R.C.: Molecular biology of HTLV. In Aaronson, S.A., Frati, L., and Verma, R. (Eds.): *Genetic and Phenotypic Markers of Tumors*. New York, Plenum Press, 1985, pp. 337-344.
  39. Wong-Staal, F., Ratner, L., Shaw, G., Hahn, B., Harper, M., Franchini, G., and Gallo, R.: Molecular biology of human T-lymphotropic retroviruses. *Cancer Res.* 1985 45:4539s-4544s.
  40. Aldovini, A., De Rossi, A., Feinberg, M.B., Wong-Staal, F., and Franchini, G.: Molecular analysis of a deletion mutant provirus of type I human T-cell lymphotropic virus: Evidence for a doubly spliced x-lor mRNA. *Proc. Natl. Acad. Sci. USA* 1986 83:38-42.
  41. Kan, N.C., Franchini, G., Wong-Staal, F., DuBois, G.C., Robey, W.G., Lautenberger, J.A., and Papas, T.S.: Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera. *Science* 1986 231:1553-1555.
  42. De Rossi, A., Franchini, G., Aldovini, A., Del Mistro, A., Chieco-Bianchi, L., Gallo, R.C., and Wong-Staal, F.: Differential response to the cytopathic effects of human T-cell lymphotropic virus type III (HTLV-III) superinfection in T4+ (helper) and T8+ (suppressor) T-cell clones transformed by HTLV-I. *Proc. Natl. Acad. Sci. USA* 1986 83:4297-4301.
  43. Franchini, G., Robert-Guroff, M., Wong-Staal, F., Ghayeb, J., Kato, I., Chang, T.W., and Chang, N.T.: Expression of the protein encoded by the 3' open reading frame of human T-cell lymphotropic virus type III in bacteria: Demonstration of its immunoreactivity with human sera. *Proc. Natl. Acad. Sci. USA* 1986 83:5282-5285.
  44. Franchini, G., Robert-Guroff, M., Grayeb, J., Chang, N.T., and Wong-Staal, F.: Cytoplasmic localization of the HTLV-III 3' orf protein in cultured T cells. *Virology* 1986 155:593-599.
  45. Franchini, G., Robert-Guroff, M., Aldovini, A., Kan, N.C., and Wong-Staal, F.: Spectrum of natural antibodies against five HTLV-III antigens in infected individuals: Correlation of antibody prevalence with clinical status. *Blood* 1987 69:437-441.
  46. Franchini, G., Gurgo, C., Guo, H.G., Gallo, R.C., Collalti, E., Fargnoli, K.A., Hall, L.F., Wong-Staal, F., and Reitz, M.S., Jr.: Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses. *Nature* 1987 328:539-542.
  47. Ranki, A., Krohn, M., Allain, J.P., Franchini, G., Valle, S.-L., Antonen, J., Leuther, M., and Krohn, K.: Long latency precedes overt seroconversion in sexually transmitted human-immunodeficiency-virus infection. *Lancet* 1987 ii:589-593.
  48. Franchini, G., Collalti, E., Arya, S.K., Fenyo, E.M., Biberfeld, G., Zagury, J.F., Kanki, P.J., Wong-Staal, F., and Gallo, R.C.: Genetic analysis of a new subgroup of human and simian T-lymphotropic retroviruses: HTLV-IV, LAV-2, SBL-6669 and STLV-IIIAGM. *AIDS Res. Hum. Retroviruses* 1987 3:11-17.
  49. Guo, H.G., Franchini, G., Collalti, E., Beaver, B., Gurgo, C., Gallo, R.C., Wong-Staal, F., and Reitz, M.S.: Structure of the long terminal repeat of simian lymphotropic virus type III (African green monkey) and its relatedness to that of HIV. *AIDS Res. Hum. Retroviruses* 1987 3:177-185.

50. Gurgo, C., Colombini, S., Reitz, M.S., Franchini, G., Collalti, E., Guo, H.-G., Wong-Staal, F., and Gallo, R.C.: Role of the human retroviruses HTLV-I, HTLV-II and HIV in leukemia and AIDS. In Giraldo, G., Beth-Giraldo, E., Clumeck, N., Gharbi, Md-R., Kyalwazi, S.K., and de The, G. (Eds.): *AIDS and Associated Cancers in Africa*. Basel, S. Karger, 1988, pp. 182-229.
51. Gurgo, C., Guo, H.G., Franchini, G., Aldovini, A., Collalti, E., Farrell, K., Wong-Staal, F., Gallo, R.C., and Reitz, M.S., Jr.: Envelope sequences of two new United States HIV-1 isolates. *Virology* 1989 164:531-536.
52. Clark, J.W., Gurgo, C., Franchini, G., Gibbs, W.N., Lofters, W., Neuland, C., Mann, D., Saxinger, C., Gallo, R.C., and Blattner, W.A.: Molecular epidemiology of HTLV-I-associated non-Hodgkin's lymphomas in Jamaica. *Cancer* 1989 61:1477-1482.
53. Franchini, G., Fargnoli, K.A., Giombini, F., Jagodzinski, L., De Rossi, A., Bosch, M., Biberfeld, G., Fenyo, E.M., Albert, J., Gallo, R.C., and Wong-Staal, F.: Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. *Proc. Natl. Acad. Sci. USA* 1989 86:2433-2437.
54. Zagury, J.F., Franchini, G., Reitz, M., Collalti, E., Starcich, B., Hall, L., Fargnoli, K., Jagodzinski, L., Guo, H.-G., Laure, F., Arya, S.K., Josephs, S., Zagury, D., Wong-Staal, F., and Gallo, R.C.: Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1. *Proc. Natl. Acad. Sci. USA* 1989 85:5941-5945.
55. Franchini, G., Rusche, J.R., O'Keefe, T.J., and Wong-Staal, F.: The human immunodeficiency virus type 2 (HIV-2) contains a novel gene encoding a 16 kD protein associated with mature virions. *AIDS Res. Hum. Retroviruses* 1989 4:243-250.
56. Franchini, G., Kanki, P.J., Bosch, M.L., Fargnoli, K., and Wong-Staal, F.: The simian immunodeficiency virus envelope open reading frame located after the termination codon is expressed in vivo in infected animals. *AIDS Res. Hum. Retroviruses* 1989 4:251-258.
57. Cardoso, E.A., Robert-Guroff, M., Franchini, G., Gartner, S., Moura-Nunes, J.F., Gallo, R.C., and Terrinha, A.M.: Seroprevalence of HTLV-I in Portugal and evidence for double retrovirus infection of a healthy donor. *Int. J. Cancer* 1989 43:195-200.
58. Franchini, G. and Bosch, M.L.: Genetic relatedness of the human immunodeficiency viruses type 1 and 2 (HIV-1, HIV-2) and the simian immunodeficiency virus (SIV). *Ann. NY Acad. Sci.* 1989 544:81-87.
59. Marcon, L. and Franchini, G.: Genetics and biology of human retroviruses. *Bone Marrow Transplant.* 1989 4:2-4.
60. Bosch, M.L., Earl, P.C., Fargnoli, K., Picciafuoco, S., Giombini, F., Wong-Staal, F., and Franchini, G.: Identification of the fusion peptide of primate immunodeficiency viruses. *Science* 1989 244:694-697.
61. Franchini, G.: Human and non-human primate immunodeficiency viruses: Genetic relatedness and phylogeny. *Curr. Opinion Immunol.* 1989 1:513-515.
62. Lusso, P., diMarzo Veronese, F., Ensoli, B., Franchini, G., Jemma, C., DeRocco, S.E., Kalyanaraman, V.S., and Gallo, R.C.: Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. *Science* 1990 247:848-852.
63. Franchini, G. and Wong-Staal, F.: Conserved and divergent features of human and simian immunodeficiency viruses. In Putney, S. and Bolognesi, D. (Eds.): *AIDS Vaccine Research and Clinical Trials*. New York, Marcel Dekker, 1990, pp. 107-119.
64. Chakrabarti, S., Mizukami, T., Franchini, G., and Moss, B.: Synthesis, oligomerization, and biological activity of the human immunodeficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus. *Virology* 178:134-142, 1990.
65. Franchini, G.: Genetic variation of human retroviruses as a mean to understand their origin and evolution. The use of HIV-2 in animals as a tool for the development of a vaccine for humans. In Goebel, K. (Ed.): *The Science and Culture Series (Nuclear Strategy and Technology) presented at the International Seminar on Nuclear War--10th Session: Planetary Emergencies*. Singapore, World Scientific, 1990, pp. 163-176.
66. Franchini, G., Markham, P., Gard, E., Fargnoli, K., Keubarawa, S., Jagodzinski, L., Robert-Guroff, M., Lusso, P., Ford, G., Wong-Staal, F., and Gallo, R.C.: Persistent infection of rhesus macaques with a molecular clone of human immunodeficiency virus type 2: Evidence of minimal genetic drift and low pathogenetic effects. *J. Virol.* 1990 64:4462-4467.
67. Hattori, N., Michaels, F., Fargnoli, K., Marcon, L., Gallo, R.C., and Franchini, G.: The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages. *Proc. Natl. Acad. Sci. USA* 1990 87:8080-8084.
68. McCune, J.M., Namikawa, R., Shih, C.-C., Rabin, L., and Kaneshima, H. with Response by Lusso, P., Di Marzo Veronese, F., Ensoli, B., Franchini, G., Jemma, C., DeRocco, S.E., Kalyanaraman, V.S., and Gallo, R.C.: Pseudotypes in HIV-infected mice. *Science* 1990 250:1152-1154.
69. Marcon, L., Hattori, N., Gallo, R.C., and Franchini, G.: A comparison of the genetic and biologic features of human

- and non-human immunodeficiency lentiviruses. In Giraldo, G., Salvatore, M., Piazza, M., Zarrilli, D., and Beth-Giraldo, E. (Eds.): *Biomedical and Social Developments in AIDS and Associated Tumors*. Basel, Karger, 1991, pp. 55-68.
70. Gessain, A., Louie, A., Gout, O., Gallo, R.C., and Franchini, G.: Human T-cell leukemia-lymphoma virus type I (HTLV-I) expression in fresh peripheral blood mononuclear cells from patients with tropical spastic paraparesis/HTLV-I-associated myelopathy. *J. Virol.* 1991 65:1628-1633.
  71. Marcon, L., Michaels, F., Hattori, N., Fargnoli, K., Gallo, R.C., and Franchini, G.: Dispensable role of the human immunodeficiency virus type 2 Vpx protein in viral replication. *J. Virol.* 1991 65:3938-3942.
  72. Gessain, A., Yanagihara, R., Franchini, G., Garruto, R.M., Jenkins, C.L., Ajdukiewicz, A.B., Gallo, R.C., and Gajdusek, D.C.: Highly divergent molecular variants of human T-lymphotropic virus type I from isolated populations in Papua New Guinea and the Solomon Islands. *Proc. Natl. Acad. Sci. USA* 1991 88:7694-7698.
  73. Gessain, A., Gallo, R.C., and Franchini, G.: Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations. *J. Virol* 1992. 66:2288-2295.
  74. Robert-Guroff, M., Aldrich, K., Muldoon, R., Stern, T.L., Bansal, G.P., Matthews, T.J., Markham, P.D., Gallo, R.C., and Franchini, G.: Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates. *J. Virol.* 1992 66:3602-3608.
  75. Boeri, E., Giri, A., Lillo, F., Ferrari, G., Varnier, O.E., Ferro, A., Sabbatani, S., Saxinger, C.W., and Franchini, G.: In vivo genetic variability of the human immunodeficiency virus type 2 V3 region. *J. Virol.* 66:4546-4550.
  76. Lori, F., Hall, L., Lusso, P., Popovic, M., Markham, P., Franchini, G., and Reitz, Jr., M.S.: Effect of reciprocal complementation of two defective human immunodeficiency virus type 1 (HIV-1) molecular clones on HIV-1 cell tropism and virulence. *J. Virol.* 1992 66:5553-5560.
  77. Koralnik, I.J., Gessain, A., Klotman, M.E., LoMonico, A., Berneman, Z.N., and Franchini, G.: Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type I. *Proc. Natl. Acad. Sci. USA* 1992;88:813-8817.
  78. Koralnik, I.J., Lemp, J.F., Jr., Gallo, R.C., and Franchini, G.: In vitro infection of human macrophages by human T-cell leukemia/lymphotropic virus type I (HTLV-I). *AIDS Res. Hum. Retroviruses* 1992 8:1845-1849.
  79. Gessain, A., Boeri, E., Kazadi, K., Garin, B., Salaün, J.J., Gallo, R.C., deThé, G., and Franchini, G.: Variant retroviral HTLV-I au Zaïre chez un patient ayant une neuromyélopathie chronique. Séquence nucléotidique du gène d'enveloppe. *C. R. Acad. Sci. Paris* 1992 314:159-164.
  80. Boeri, E., Gessain, A., Garin, B., Kazadi, K., de Thé, G., and Franchini, G.: Qualitative changes in the human T-cell leukemia/lymphotropic virus type I env gene sequence in the spastic versus nonspastic tropical paraparesis are not correlated with disease specificity. *AIDS Res. Hum. Retroviruses* 1993 9:1-5.
  81. Gessain, A., Boeri, E., Yanagihara, R., Gallo, R.C., and Franchini, G.: Complete nucleotide sequence of a highly divergent human T-cell leukemia (lymphotropic) virus type I (HTLV-I) variant from Melanesia: Genetic and phylogenetic relationship to HTLV-I strains from other geographical regions. *J. Virol.* 1993 67:1015-1023.
  82. Koralnik, I.J., Fullen, J., and Franchini, G.: The p12I, p13II, and p30II proteins encoded by human T-cell leukemia/lymphotropic virus type I open reading frames I and II are localized in three different cellular compartments. *J. Virol.* 1993 67:2360-2366.
  83. Balotta, C., Lusso, P., Crowley, R., Gallo, R.C., and Franchini, G.: Antisense phosphorothioate oligodeoxynucleotides targeted to the vpr gene inhibit human immunodeficiency virus type 1 replication in primary human macrophages. *J. Virol.* 1993 67:4409-4414.
  84. Michaels, F.H., Hattori, N., Gallo, R.C., and Franchini, G.: The human immunodeficiency virus type 1 (HIV-1) Vif protein is located in the cytoplasm of infected cells and its effect on viral replication is equivalent in HIV-2. *AIDS Res. Hum. Retroviruses* 1993 9:1025-1030.
  85. Franchini, G., Mulloy, J.C., Koralnik, I.J., LoMonico, A., Sparkowski, J.J., Andresson, T., Goldstein, D.J., and Schlegel, R.: The human T-cell leukemia/lymphotropic virus type I p12I protein cooperates with the E5 oncoprotein of bovine papillomavirus in cell transformation and binds the 16-kilodalton subunit of the vacuolar H<sup>+</sup> ATPase. *J. Virol.* 1993 67:7701-7704.
  86. Tartaglia, J., Franchini, G., Robert-Guroff, M., Abimuku, A., Benson, J., Limbach, K., Wills, M., Gallo, R.C., and Paoletti, E.: Highly attenuated poxvirus vector strains, NYVAC and ALVAC, in retrovirus vaccine development. In Robert, O. (Ed.): *Huitième Colloque Des Cent Gardes - 1993 (Proceedings)*. Paris, Foundation Merieux, 1993, pp. 293-298.
  87. Benson, J., Tschachler, E., Gessain, A., Yanagihara, R., Gallo, R.C., and Franchini, G.: Cross-neutralizing antibodies against cosmopolitan and Melanesian strains of human T cell leukemia/lymphotropic virus type I in sera from inhabitants of Africa and the Solomon Islands. *AIDS Res. Hum. Retroviruses* 1994 10:91-96.

88. Gessain, A., Koralknik, I.J., Fullen, J., Boeri, E., Mora, C., Blank, A., Salazar-Grueso, E.F., Kaplan, J., Saxinger, W.C., Davidson, M., Lairmore, M.D., Levine, P., and Franchini, G.: Phylogenetic study of ten new HTLV-I strains from the Americas. *AIDS Res. Hum. Retroviruses* 1994 10:103-106.
89. Koralknik, I.J., Boeri, E., Saxinger, W.C., LoMonico, A., Fullen, J., Gessain, A., Guo, H.G., Gallo, R.C., Markham, P., Kalyanaraman, V., Hirsch, V., Allan, J., Murthy, K., Alford, P., Slattery, J.P., O'Brien, S.J., and Franchini, G.: Phylogenetic associations of human and simian T-cell leukemia/lymphotropic virus type I strains: Evidence for interspecies transmission. *J. Virol.* 1994 68:2693-2707
90. Franchini, G. and Reitz, M.S., Jr.: Phylogenesis and genetic complexity of the nonhuman primate retroviridae. *AIDS Res. Hum. Retroviruses* 1994 10:1047-1060.
91. Giri, A., Markham, P., Digilio, L., Hurteau, G., Gallo, R.C., and Franchini, G.: Isolation of a novel simian T-cell lymphotropic virus from *Pan paniscus* that is distantly related to the human T-cell leukemia/lymphotropic virus types I and II. *J. Virol.* 1994 68:8392-8395.
92. Nerurkar, V.R., Song, K.J., Bastian, I.B., Garin, B., Franchini, G., and Yanigihara, R.: Genotyping of human T cell lymphotropic virus type I using Australo-Melanesian topotype-specific oligonucleotide primer-based polymerase chain reaction: Insights into viral evolution and dissemination. *J. Infect. Dis.* 1994 170:1353-1360.
93. Franchini, G., Tartaglia, J., Benson, J., Robert-Guroff, M., Abimiku, A., Paoletti, E., and Gallo, R.C.: NYVAC/ALVAC recombinant vectors as vaccines against HIV-2 and HTLV-1. In Robert, O. (Ed.): *Neuvième Colloque Des Cent Gardes - 1994 (Proceedings)*. Paris, Foundation Merieux, 1994, pp. 267-273.
94. Franchini, G., Tartaglia, J., Markham, P., Benson, J., Fullen, J., Wills, M., Arp, J., Dekaban, G., Paoletti, E., and Gallo, R.C.: Highly attenuated HTLV type I env poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits. *AIDS Res. Hum. Retroviruses* 11:307-313, 1995.
95. Franchini, G. and Streicher, H.: Human T-cell leukemia virus. In Young, N. (Ed.): *Viruses as Agents of Haematological Disease*. London, Baillière Tindall, 1995, pp. 131-148.
96. Abimiku, A.G., Franchini, G., Tartaglia, J., Aldrich, K., Myagkikh, M., Markham, P.D., Chong, P., Klein, M., Kieny, M.P., Paoletti, E., Gallo, R.C., and Robert-Guroff, M.: HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. *Nature Med.* 1995 1:321-329.
97. Franchini, G., Robert-Guroff, M., Tartaglia, J., Aggarwal, A., Abimiku, A., Benson, J., Markham, P., Limbach, K., Hurteau, G., Fullen, J., Aldrich, K., Miller, N., Sadoff, J., Paoletti, E., and Gallo, R.C.: Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. *AIDS Res. Hum. Retroviruses* 1995 11:909-920.
98. Migone, T.S., Lin, J.X., Cereseto, A., Mulloy, J.C., O'Shea, J.J., Franchini, G., and Leonard, W.J.: Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. *Science* 1995 269:79-81.
99. Taylor, J., Meignier, B., Tartaglia, J., Languet, B., VanderHoeven, J., Franchini, G., Trimarchi, C., and Paoletti, E.: Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. *Vaccine* 1995 13:539-549.
100. Ciminale, V., D'Agostino, D.M., Zotti, L., Franchini, G., Felber, B.K., and Chieco-Bianchi, L.: Expression and characterization of proteins produced by mRNAs spliced into the X region of the human T-cell leukemia/lymphotropic virus type II. *Virology* 1995 209:445-456.
101. Boeri, E., Abecasis, C., Varnier, O.E., and Franchini, G.: Analysis of HTLV-I env gene sequence from an Italian polytransfused patient: Evidence for a Zairian HTLV-I in Sicily. *AIDS Res. Hum. Retroviruses* 11:649-651, 1995.
102. Abimiku, A.G., Franchini, G., Aldrich, K., Myagkikh, M., Markham, P., Gard, E., Gallo, R.C., and Robert-Guroff, M.: Humoral and cellular immune responses in rhesus macaques infected with human immunodeficiency virus type 2. *AIDS Res. Hum. Retroviruses* 1995 11:383-393.
103. Koralknik, I.J., Mulloy, J.C., Andresson, T., Fullen, J., and Franchini, G.: Mapping of the intermolecular association of the human T cell leukaemia/lymphotropic virus type I p12I protein and the vacuolar H<sup>+</sup>-ATPase 16 Kd subunit protein. *J. Gen. Virol.* 1995 76:1909-1916.
104. Franchini, G.: Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. *Blood* 1995 86:3619-3639.
105. Dekaban, G.A., Digilio, L., and Franchini, G.: The natural history and evolution of human and simian T cell leukemia/lymphotropic viruses. In Hartl, D., O'Brain, S., and Kafatos, F. (Eds.): *Current Opinion In Genetics & Development*, Vol. 5. United Kingdom, Current Biology Ltd., 1995, pp. 807-813.
106. Yanagihara, R., Saitou, N., Nerurkar, V., Song, K., Bastian, I., Franchini, G., and Gajdusek, C.: Molecular Phylogeny and Dissemination of Human T-Cell Lymphotropic Virus Type I Viewed With the Context of Primate Evolution and Human Migration. *Cell. Mol. Biol.* 1995 41:S145-S161.
107. Franchini, G., Benson, J., Gallo, R., Paoletti, E., and Tartaglia, J.: Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I. *AIDS Res. Hum. Retroviruses* 1996 12:407-408.

108. Voevodin, A., Samilchuk, E., Schätzl, H., Boeri, E., and Franchini, G.: Interspecies transmission of macaque simian T-cell leukemia/lymphoma virus type 1 in baboons resulted in an outbreak of malignant lymphoma. *J. Virol.* 1996 70:1633-1639.
109. Dekaban G., Coulthart, M., and Franchini, G.: Natural history of HTLVs/STLVs. In Hollsberg, P. (Ed.): **Human T-cell Lymphotropic Virus Type I**. England, Wiley, J. & Sons, Ltd., 1996.
110. Franchini, G.: Considerations on the development of AIDS vaccines. In: **Molecular Biology of Hematopoiesis**, Vol. 2. Andover, Intercept Ltd., 1996.
111. Cereseto, A., Mulloy, J.C., and Franchini, G.: Insights on the pathogenicity of the human T-lymphotropic/leukemia virus types I and II. *J. Acquir. Immune Defic. Syndro. Hum. Retrovirol.* 1996 Vol. 13 (Suppl 1):S69-S75.
112. Safai, B., Huang, J.-L., Boeri, E., Farid, R., Raafat, J., Schutzer, P., Ahkami, R., and Franchini, G.: Prevalence of HTLV-I infection in Iran: A serological and genetic study. *AIDS Res. Hum. Retroviruses* 1996 12:1185-1190.
113. Mulloy, J.C., Crowley, R.W., Fullen, J., Leonard, W.J., and Franchini, G.: The human T-cell leukemia/lymphotropic virus type 1 p12I protein binds the interleukin-2 receptor b and gc chains and affects their expression on the cell surface. *J. Virol.* 1996 70:3599-3605.
114. Andersson, S., Mäkitalo B., Thorstensson, R., Franchini, G., Tartaglia, J., Limbach, K., Paoletti, E., Putkonen, P., and Biberfeld, G.: Immunogenicity and protective efficacy of an HIV-2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. *J. Infect. Dis.* 1996 174:977-985.
115. Myagkikh, M, Alipanah, S., Markham, P., Tartaglia, J., Paoletti, E., Gallo, R. C. Franchini, G., and Robert-Guroff, M.: Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. *AIDS Res. Hum. Retroviruses* 1996 12:985-991.
116. Cereseto, A., Diella, F., Cara, A., Mulloy, J.C., Grassman, R., Franchini, G., and Klotman, M.E.: RAPID COMMUNICATION p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type (HTLV-I) transformed T-cells. *Blood* 1996 88:1551-1560.
117. Cereseto, A., Berneman, Z., Koralnik, I.J., Franchini, G., and Klotman, M.E.: Differential expression of alternatively splices pX mRNAs in HTLV-I-infected cell lines. *Leukemia* 1997 11:866-870.
118. Digilio, L., Giri, A., Cho, N., Slattery, J., Markham, P., and Franchini, G.: The simian T-lymphotropic leukemia viruses from *Pan paniscus* (STLVpan-p) belong to the type II family and infect Asian macaques. *J. Virol.* 199771:3684-3692.
119. Giri, A., Slattery, J.P., Walid, H., Gessain, A., Rivadeneira, E., Desrosiers, R.C., Rosen, L., Anthony, R., Pamungkas, J., Iskandriati, D., Richards, A.L., Herve, V., O'Brien, McClure, H., S.J., and Franchini, G.: Tax gene sequences provide support for an ancient Asian origin of simian and human T-cell leukemia/lymphotropic viruses. *Virology* 1997 231:96-104.
120. Abimiku, A.G., Robert-Guroff, M., Benson, J., Tartaglia, J., Paoletti, E., Gallo, R.C., Markham, P.D., and Franchini, G.: Long-term survival of SIVmac251-infected macaques previously immunized with NYVAC-SIV vaccines. *J. Acquir. Immune Defic. Syndro. Hum. Retrovirol.* 199715:S78-S85.
121. Lori, F., Gallo, R.C., Malykh, A., Cara, A., Romano, J., Markham, P., and Franchini, G.: Didanosine, but not high doses of hydroxyurea, rescue pigtailed macaque from a lethal dose of SIVsmmpbj14. *AIDS Res. Hum. Retroviruses* 1997 13:1084-1088.
122. Takemoto, S., Mulloy, J., Cereseto, A., Migone, T.S., Patel, B.K.R., Matsuoka, M., Yamaguchi, K., Takatsuki, K., Kamihira, S., White, J.D., Leonard, W.J, Waldmann, T., and Franchini, G.: Proliferation of adult T-cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. *Proc. Natl. Acad. Sci. USA* 1997 94:13897-13902.
123. Tartaglia, J., Benson, J., Cornet, B., Cox, W.I., El Habib, R., Excler, J.-L., Franchini, G., Goebel, S., Jacobs, B.L., Klein, M., Limbach, K., Martinez, H., Meignier, B., Pincus, S., and Plotkin, S.: Potential improvements for poxvirus-based immunization vehicles. In Girard, M., and Dodet, B., (Eds.): **Onzieme Colloque Des Cent Gardes - 1997 (Proceedings)**. Paris, Pasteur Merieux, 1997, pp. 187-197.
124. Tschachler, E., and Franchini, G: Infective dermatitis: a pabulum for HTLV-I leukemogenesis? *Arch. Dermat.* 1998 134:487-488.
125. Benson, J., Chougnet, C., Robert-Guroff, M., Montefiori, D., Markham, P., Shearer, G., Gallo, R.C., Cranage, M., Paoletti, E., Limbach, K., Venzon, D., Tartaglia, J., and Franchini, G.: Recombinant vaccine-induced protection against the highly pathogenic SIVmac251: dependence on route of challenge exposure. *J. Virol.* 1998 72:4170-4182.
126. Mulloy, J.C., Migone, T.-S., Ross, T.M., Ton, N., Green, P.L., Leonard, W.J., and Franchini, G.: Human and simian T-cell leukemia viruses type II (HTLV-II and STLV-2pan-p) transform T-cells independently of Jak/STAT activation. *J. Virol.* 1998 72:4408-4412.
127. Secchiero, P., Bertolaso, L., Casareto, L., Gibellini, D., Vitale, M., Bemis, K., Aleotti, A., Capitani, S., Franchini, G., Gallo, R.C., and Zauli, G.: Human herpesvirus 7 infection induces profound cell cycle perturbations coupled to



- disregulation of cdc2 and cyclin B and polyploidization of CD4+ T-cells. *Blood* 1998 92:1685-1696.
128. Mulloy, J.C., Kislyakova, T., Cereseto, A., Casareto, L., LoMonico, A., Fullen, J., Lorenzi, M.V., Cara, A., Nicot, C., Giam, C.-Z., and Franchini, G.: HTLV-I Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain. *J. Virol.* 1998 72:8852-8860.
  129. Franchini, G.: Vaccini anti HIV: stato dell'arte e prospettive future. *In Filice, G. (Ed.): Patogenesi, Diagnosi e Terapia della Infezione da HIV.* Milano, Edizioni Ulisse, Segrate, 1998, pp. 257-262.
  130. Richards, A.L., Giri, A., Iskandriati, D., Pamungkas, J., Sie, A., Rosen, L., Anthony, R.L., and Franchini, G.: Simian T-lymphotropic virus type I infection among wild-caught Indonesian pig-tailed macaques (*Macaca nemestrina*). *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* 1998 19:542-545.
  131. Tschachler, E., Reitz, M.S., Jr., and Franchini, G.: Human retroviral disease: human T-lymphotropic viruses. In Freedberg, I.M., Eisen, A.Z., Wolff, K., Austen, K.F., Goldsmith, L.A., Katz, S.I., and Fitzpatrick, T.B. (Eds.): *Fitzpatrick's Dermatology in General Medicine.* New York, McGraw-Hill, 1999, pp. 2497-2505.
  132. Leno, M., Carter, L., Venzon, D.J., Romano, J., Markham, P.D., Limbach, K., Tartaglia, J., Paoletti, E., Benson, J., Franchini, G., and Robert-Guroff, M.: CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy. *AIDS Res. Hum. Retroviruses* 1999 15:461-470.
  133. Cereseto, A., Washington-Parks, R., Rivadeneira, and Franchini, G.: Limiting amounts of p27kip1 correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells. *Oncogene* 1999 18:2441-2450.
  134. Trovato, R., Mulloy, J.C., Johnson, J., Takemoto, S., de Oliveira, M.P., and Franchini, G.: A lysine-to-arginine change found in natural alleles of the HTLV-I p12I protein greatly influences its stability. *J. Virol.* 1999 73:6460-6467.
  135. Slattery, J.P., Franchini, G., and Gessain, A.: Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses. *Genome Res.* 1999 9:525-40.
  136. Cereseto, A., Kislyakova, T., Washington-Parks, R., Nicot, C., and Franchini, G.: Differential response to genotoxic stress in immortalized or transformed HTLV-I-infected T-cells. *J. Gen. Virol.* 1999 80:1575-1581.
  137. Ciminale, V., Zotti, L., D'Agostino, D.M., Ferro, T., Casareto, L., Franchini, G., Bernardi, P., Chieco-Bianchi, L.: Mitochondrial targeting of the p13II protein encoded by the x-II ORF of human T-cell leukemia/lymphotropic virus type I (HTLV-I). *Oncogene* 1999 18:4505-4514.
  138. Ekholm, D., Mulloy, J.C., Gao, G., Degerman, E., Franchini, G., and Manganiello, V.C.: Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes. *Biochem. Pharmacol.* 1999 58:935-950.
  139. Franchini, G., Cereseto, A., Trynieszewska, E., Rivadeneira, E., Kislyakova, T., Mulloy, J.C., Takemoto, S., Casareto, L., Nicot, C., and Trovato, R.: Telomerase activation, rearrangement, and inhibition of cell-cycle inhibitors in human T-cells immortalized or transformed by HTLV-I. In Semmes, O.J., and Hammarskjold, M.-L. (Eds.): *Molecular Pathogenesis of HTLV-I: A Current Perspective.* Arlington: ABI Professional Publications, 1999.
  140. Rivadeneira ED, Ferrari MG, Jarrett RF, Armstrong AA, Markham P, Birkebak T, Takemoto S, Johnson-Delaney C, Pecon-Slattery J, Clark EA, Franchini G. A novel Epstein-Barr virus-like virus, HV(MNE), in a *Macaca nemestrina* with mycosis fungoides. *Blood.* 1999 Sep 15;94(6):2090-101. PubMed PMID: 10477739.
  141. Beer, B.E., Bailes, E., Dapolito, G., Campbell, B.J., Goeken, R., Axthelm, M., Markham, P., Bernard, J., Zagury, D., Franchini, G., Sharp, P., and Hirsch, V.M.: Patterns of genomic sequence diversity among their simian immunodeficiency viruses suggest that I=hoest monkeys (*Cercopithecus lhoesti*) are a natural lentivirus reservoir. *J. Virol.* 2000 74:3892-3989.
  142. Trovato, R., Cereseto, A., Takemoto, S., Gessain, A., Watanabe, T., Waldmann, T., and Franchini, G.: Deletion of the p16<sup>INK4A</sup> gene in *ex vivo* acute ATLL cells and methylation of p16<sup>INK4A</sup> promoter in HTLV-I-infected T-cell lines. *AIDS Res. Hum. Retroviruses* 2000 16:709-713.
  143. Takemoto, S., Trovato, R., Cereseto, A., Nicot, C., Kislyakova, T., Casareto, L., Waldmann, T., Torelli, G., and Franchini, G.: p53 stabilization and functional impairment in the absence of genetic mutation or alteration of the p14<sup>ARF</sup>-MDM2 loop in *ex vivo* and cultured ATLL T-cells. *Blood* 2000 15:3939-3944.
  144. Stevceva, L., Abimiku, A., and Franchini, G.: Targeting the mucosa: genetically engineered vaccines and mucosal immune responses. *Genes and Immunity* 2000 1:308-315.
  145. Nicot, C., Mahieux, R., Takemoto, S., and Franchini, G.: Bcl-XL is upregulated by HTLV type I and type II in vitro and in *ex vivo* ATLL samples. *Blood* 2000 96:275-281,
  146. Kuroda, M.J., Schmitz, J.E., Lekutis, C., Nickerson, C.E., Lifton, M.A., Franchini, G., Harouse, J.M., Cheng-Mayer, C., and Letvin, N.L.: Human immunodeficiency virus type 1 envelope epitope-specific CD4(+) T lymphocytes in simian/human immunodeficiency virus-infected and vaccinated rhesus monkeys detected using a peptide-major histocompatibility complex class II tetramer. *Journal of Virology* 2000 74:8751-8756.
  147. Dekaban, G.A., Peters, A.A., Mulloy, J.C., Johnson, J.M., Trovato, R., Rivadeneira, E., and Franchini, G.: The

- HTLV-I orf I protein is recognized by serum antibodies from naturally infected humans and experimentally infected rabbits. *Virology* 2000 274:86-93,
148. Dekaban, G. A., Peters, A., Arp, J., and Franchini, G.: Vaccine development against HTLV-I in human retroviral infection: immunological and molecular theories. In Ugen, K., Bendinelli, M., and Friedman, H. (Eds.): *Infectious Agents and Pathogenesis*. New York: Plenum Publishing, 2000, pp. 109-142.
  149. Margolis, L., Glushakova, S., Chougnet, C., Shearer, G., Markham, P., Robert-Guroff, M., Benveniste, R., Miller, C.J., Cranage, M., Hirsch, V., and Franchini, G.: Replication of simian immunodeficiency virus (SIV) in ex vivo lymph nodes as a means to assess susceptibility of macaques in vivo. *Virology* 2000 275:391-397.
  150. Nicot, C., Mahieux, R., Opavsky, R., Cereseto, A., Wolff, L., Brandy, J.N., and Franchini, G.: HTLV-I Tax transrepresses the human c-Myb promoter independently of its interaction with CBP or p300. *Oncogene* 2000 19:2155-2164,
  151. Hel, Z., Poudyal, M., Tsai, W.-P., Giuliani, L., Woodward, R., Chougnet, C., Shearer, G., Altman, J., Watkins, D., Bischofberger, N., Abimiku, A., Markham, P., Tartaglia, J., and Franchini, G.: Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. *Nature Medicine* 6:1140-1146, 2000. Commentary in: Walker, B.D., and Rosenberg, E.S.: Containing HIV after infection. *Nature Medicine* 2000 6:1094-1095.
  152. Nicot, C., Opavsky, R., Mahieux, R., Johnson, J.M., Brady, J.N., Wolff, L., and Franchini, G.: Tax oncoprotein transrepresses endogenous B-Myb promoter activity in human T-cells. *AIDS Research and Human Retroviruses* 16:1629-1632, 2000.
  153. Patterson, L.J., Peng, B., Abimiku, A.G., Aldrich, K., Murty, L., Markham, P.D., Kalyanaraman, V.S., Alvord, W.G., Tartaglia, J., Franchini, G., and Robert-Guroff, M.: Cross-protection in NYVAC-HIV-1 immunized/HIV-2 challenged but not in NYVAC-HIV-2 immunized/SHIV challenged rhesus macaques. *AIDS* 2000 14:2445-2455,
  154. Johnson, J.M., Mulloy, J.C., Ciminale, V., Fullen, J., Nicot, C., and Franchini, G.: The MHC class I heavy chain is a common target of the small proteins encoded by the 3' end of HTLV-1 and -2. *AIDS Research and Human Retroviruses* 2000 16:1777-1781.
  155. D'Agostino, D.M., Zotti, L., Ferro, T., Franchini, G., Chieco-Bianchi, L., and Ciminale, V.: The p13II protein of HTLV type 1: comparison with mitochondrial proteins encoded by other human viruses. *AIDS Research and Human Retroviruses* 2000 16:1765-1770,
  156. Franchini, G., Ambinder, R.F., and Barry, M.: Viral disease in hematology. In: *Education Book*. Washington, D.C.: American Society of Hematology, 2000, pp. 409-423.
  157. Kazanji, M., Tartaglia, J., Franchini, G., de Thoisy, B., Talarmin, A., Contamin, H., Gessain, A., and de The, G.: Immunogenicity and protective efficacy of recombinant HTLV-I NYVAC and naked DNA vaccine candidates in squirrel monkeys (*Saimiri sciureus*). *Journal of Virology* 2001 75: 5939-5948,.
  158. Johnson JM, Harrod R, Franchini G. Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus type-1 (HTLV-1). *Int J Exp Pathol*. 2001 Jun;82(3):135-47.
  159. Johnson, J.M., Nicot, C., Fullen, J., Ciminale, V., Casareto, L., Mulloy, J.C., Jacobson, S., and Franchini, G.: Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by HTLV-1 p12<sup>1</sup> protein. *Journal of Virology* 2001 Jul 75: 6086-6094,.
  160. Nicot, C., Mulloy, J.C., Ferrari, M.G., Johnson, J.M., Fu, K., Fukumoto, R., Trovato, R., Fullen, J., Leonard, W.J., and Franchini, G.: The HTLV-1 p12<sup>1</sup> protein enhances STAT5 activation and decreases the IL-2 requirement for proliferation of primary human PBMC. *Blood* 2001 Aug 98: 823-829,.
  161. Stevceva L, Tryniszewska E, Hel Z, Nacsa J, Kelsall B, Washington Parks R, Franchini G. Differences in time of virus appearance in the blood and virus-specific immune responses in intravenous and intrarectal primary SIVmac251 infection of rhesus macaques; a pilot study. *BMC Infect Dis* 2001;1(1):9.
  162. Ferrari MG, Rivadeneira ED, Jarrett R, Stevceva L, Takemoto S, Markham P, Franchini G. HV<sub>MNE</sub>, a novel lymphocryptovirus related to Epstein-Barr virus, induces lymphoma in New Zealand white rabbits. *Blood*. 2001 Oct 1;98(7):2193-9.
  163. Nicot C, Mahieux R, Pise-Masison C, Brady J, Gessain A, Yamaoka S, Franchini G. HTLV-I Tax represses c-Myb-dependent transcription through activation of the NF-kappa B pathway and modulation of coactivator usage. *Mol Cell Biol*. 2001 Nov;21(21):7391-402.
  164. Hel Z, Nacsa J, Kelsall B, Tsai WP, Letvin N, Parks RW, Tryniszewska E, Picker L, Lewis MG, Edghill-Smith Y, Moniuszko M, Pal R, Stevceva L, Altman JD, Allen TM, Watkins D, Torres JV, Berzofsky JA, Belyakov IM, Strober W, Franchini G. Impairment of Gag-specific CD8+ T cell function in mucosal and systemic compartments of SIVmac251 and SHIVKU2 infected macaques. *J Virol* 2001 Dec;75(23):11483-95.
  165. Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsa J, Watkins DI, Allen TM, Sette A, Altman J, Woodward R, Markham PD, Clements JD, Franchini G, Strober W, Berzofsky JA. Mucosal AIDS vaccine reduces

- disease and viral load in gut reservoir and blood after mucosal infection of macaques. *Nat Med* 2001 Dec;7(12):1320-6.
166. Hel Z, Tsai WP, Thornton A, Nacsa J, Giuliani L, Tryniszewska E, Poudyal M, Venzon D, Wang X, Altman J, Watkins DI, Lu W, von Gegerfelt A, Felber BK, Tartaglia J, Pavlakis GN, Franchini G. Potentiation of Simian Immunodeficiency Virus (SIV)-Specific CD4(+) and CD8(+) T Cell Responses by a DNA-SIV and NYVAC-SIV Prime/Boost Regimen. *J Immunol* 2001 Dec 15;167(12):7180-7191.
  167. Mothe BR, Horton H, Carter DK, Allen TM, Liebl ME, Skinner P, Vogel TU, Fuenger S, Vielhuber K, Rehrauer W, Wilson N, Franchini G, Altman JD, Haase A, Picker LJ, Allison DB, Watkins DI. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. *J Virol* 2002 Jan;76(2):875-84.
  168. Stevceva L, Kelsall B, Nacsa J, Moniuszko M, Hel Z, Tryniszewska E, Franchini G. Cervicovaginal Lamina Propria Lymphocytes: Phenotypic Characterization and Their Importance in Cytotoxic T-Lymphocyte Responses to Simian Immunodeficiency Virus SIV(mac251). *J Virol* 2002 Jan 1;76(1):9-18.
  169. Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, Tryniszewska E, Lewis MG, VanCott TC, Hirsch V, Woodward R, Gibson A, Grace M, Dobratz E, Markham PD, Hel Z, Nacsa J, Klein M, Tartaglia J, Franchini G. ALVAC-SIV-gag-pol-env-Based Vaccination and Macaque Major Histocompatibility Complex Class I (A\*01) Delay Simian Immunodeficiency Virus SIV(mac)-Induced Immunodeficiency. *J Virol* 2002 Jan 1;76(1):292-302.
  170. Pombo-de-Oliveira MS, Dobbin JA, Loureiro P, Borducchi D, Maia RC, Fernandes MA, Cavalcanti GB, Takemoto S, Franchini G. Genetic mutation and early onset of T-cell leukemia in pediatric patients infected at birth with HTLV-I. *Leuk Res* 2002 Feb;26(2):155-61.
  171. Santra S, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE, Lord CI, Pal R, Franchini G, Letvin NL. Recombinant Canarypox Vaccine-Elicited CTL Specific for Dominant and Subdominant Simian Immunodeficiency Virus Epitopes in Rhesus Monkeys. *J Immunol* 2002 Feb 15;168(4):1847-53.
  172. Nicot CP, Johnson JM, Franchini G. HTLV-I. In *Wiley Encyclopedia of Molecular Medicine. New York, John Wiley & Sons*, 2002, pp. 1676-1681.
  173. Hel Z, Johnson JM, Tryniszewska E, Tsai W-P, Harrod R, Fullen J, Tartaglia J, Franchini G. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. *Vaccine*. 2002 Aug 19;20(25-26):3171-3186.
  174. Johnson JM, Franchini G. Retroviral proteins that target the major histocompatibility complex class I. *Virus Res*. 2002 Sep 88(1-2):119-127.
  175. Hel Z, Tryniszewska E, Tsai WP, Johnson JM, Harrod R, Fullen J, Kalyanaraman VS, Altman JD, McNally J, Karpova T, Felber BK, Tartaglia J, Franchini G. Design and In Vivo Immunogenicity of a Polyvalent Vaccine Based on SIVmac Regulatory Genes. *DNA Cell Biol* 2002 Sep;21(9):619-26.
  176. Stevceva L, Alvarez X, Lackner AA, Tryniszewska E, Kelsall B, Nacsa J, Tartaglia J, Strober W, Franchini G. Both Mucosal and Systemic Routes of Immunization with the Live, Attenuated NYVAC/Simian Immunodeficiency Virus SIV(gpe) Recombinant Vaccine Result in Gag-Specific CD8(+) T-Cell Responses in Mucosal Tissues of Macaques. *J Virol* 2002 Nov 15;76(22):11659-11676.
  177. Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW, Montefiori DC, Felber BK, Tartaglia J, Pavlakis GN, Franchini G. Containment of Simian Immunodeficiency Virus Infection in Vaccinated Macaques: Correlation with the Magnitude of Virus-Specific Pre- and Postchallenge CD4(+) and CD8(+) T Cell Responses. *J Immunol* 2002 Nov 1;169(9):4778-4787.
  178. Tryniszewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, Venzon D, Hel Z, Parks RW, Moniuszko M, Tartaglia J, Smith KA, Franchini G. Vaccination of Macaques with Long-Standing SIVmac251 Infection Lowers the Viral Set Point After Cessation of Antiretroviral Therapy. *J Immunol* 2002 Nov 1;169(9):5347-5357.
  179. Franchini G, Nacsa J, Hel Z, Tryniszewska E. Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model. *Vaccine* 2002 Dec 19;20 Suppl 4:A52-60.
  180. Hel Z, Nacsa J, Tsai WP, Thornton A, Giuliani L, Tartaglia J, Franchini G. Equivalent Immunogenicity of the Highly Attenuated Poxvirus-Based ALVAC-SIV and NYVAC-SIV Vaccine Candidates in SIVmac251-Infected Macaques. *Virology* 2002 Dec 5;304(1):125-34.
  181. Nacsa J, Stanton J, Kunstman KJ, Tsai WP, Watkins DI, Wolinsky SM, Franchini G. Emergence of cytotoxic T lymphocyte escape mutants following antiretroviral treatment suspension in rhesus macaques infected with SIVmac251. *Virology* 2003 Jan 5;305(1):210-8.
  182. Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, Giardina S, Hecht TT, Hill BJ, Komschlies K, Tomaszewski J, Franchini G, Mackall CL. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. *Blood* 2003 Mar 15;101(6):2294-2299.
  183. Harrod R, Nacsa J, Van Lint C, Hansen J, Karpova T, McNally J, Franchini G. Human Immunodeficiency Virus Type-1 Tat/Co-activator Acetyltransferase Interactions Inhibit p53Lys-320 Acetylation and p53-responsive

- Transcription. *J Biol Chem* 2003 Apr 4;278(14):12310-12318.
184. Johnson JM, Fukumoto R, Franchini G. Functional role of the HTLV-1 p12<sup>I</sup> protein. In Sugamura K, Uchiyama T, Matsuoka M, Kannagi M (Eds.): *Two Decades of Adult T-Cell Leukemia and HTLV-1 Research*. Tokyo, Japan Scientific Societies Press, and Basel, Switzerland, S. Karger AG, 2003, pp. 103-113.
  185. Franchini G. Modeling immune intervention strategies for HIV-1 infection of humans in the macaque model. *Clinical and Applied Immunology Reviews* 2003 May;3(6):289-306.
  186. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, Wilson WH. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. *Blood*. 2003 Jun 15;101(12):4653-9.
  187. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. *Proc Natl Acad Sci U S A*. 2003 Aug 5;100(16):9458-63. Epub 2003 Jul 17. PubMed PMID: 12869693; PubMed Central PMCID: PMC170940.
  188. Radaelli A, Nacsa J, Tsai WP, Edghill-Smith Y, Zanotto C, Elli V, Venzon D, Trynieszewska E, Markham P, Mazzara GP, Panicali D, De Giuli Morghen C, Franchini G. Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251. *Virology*. 2003 Jul 20;312(1):181-95. PubMed PMID: 12890631.
  189. Edghill-Smith Y, Venzon D, Karpova T, McNally J, Nacsa J, Tsai W-P, Trynieszewska E, Moniuszko M, Manischewitz J, King LR, Snodgrass SJ, Parrish J, Markham P, Sowers M, Martin D, Lewis MG, Berzofsky JA, Belyakov IM, Moss B, Tartaglia J, Bray M, Hirsch V, Golding H, Franchini G. Modeling a safer smallpox-vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. *J Infect Dis* 2003 Oct 15;188(8):1181-91.
  190. Moniuszko M, Brown C, Pal R, Trynieszewska E, Tsai WP, Hirsch VM, Franchini G. High frequency of virus-specific CD8<sup>+</sup> T cells in the central nervous system of macaques chronically infected with SIVmac251. *J Virol* 2003 Nov 15;77(22):12346-51.
  191. Franchini G, Nicot C, Johnson JM. Seizing of T-cells by human T-cell leukemia/lymphoma virus type 1. In Vande Woude GF, Klein G (Eds.): *Advances in Cancer Research*. San Diego, Academic Press, 2003, pp. 69-132.
  192. Franchini G, Fukumoto R, Fullen JR. T-cell control by human T-cell leukemia/lymphoma virus type 1. *Int J Hematol* 2003 Nov;78(4):280-96.
  193. Ferrari MG, Stevceva L, Markham P, Franchini G. Species-specific transformation of T cells by HV<sub>MNE</sub>. *Virology*. 2003 Dec 20;317(2):299-307.
  194. Nacsa J, Radaelli A, Edghill-Smith Y, Venzon D, Tsai WP, De Giuli Morghen C, Panicali D, Tartaglia J, Franchini G. Avipox-based SIV vaccines elicit a high frequency of SIV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses in vaccinia-experienced SIVmac251-infected macaques. *Vaccine*. 2004 Jan 26; 22(5-6): 598-607.
  195. Nicot C, Dundr M, Johnson JM, Fullen JR, Alonzo N, Fukumoto R, Princler GL, Derse D, Misteli T, Franchini G. HTLV-1-encoded p30(II) is a post-transcriptional negative regulator of viral replication. *Nat Med*. 2004 Feb;10(2):197-201.
  196. Stevceva L, Moniuszko M, Alvarez X, Lackner AA, Franchini G. Functional simian immunodeficiency virus Gag-specific CD8<sup>+</sup> intraepithelial lymphocytes in the mucosae of SIVmac251- or simian-human immunodeficiency virus KU2-infected macaques. *Virology*. 2004 Feb 20;319(2):190-200.
  197. Belshe R, Franchini G, Girard MP, Gotch F, Kaleebu P, Marthas ML, McChesney MB, McCullough R, Mhalu F, Salmon-Ceron D, Sekaly RP, van Rompay K, Verrier B, Wahren B, Weissenbacher M. Support for the RV144 HIV vaccine trial. *Science*. 2004 Jul 9;305(5681):177-80.
  198. Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. *Expert Rev Vaccines*. 2004 Aug;3 Suppl 1:S75-88.
  199. Moniuszko M, Fry T, Tsai WP, Morre M, Assouline B, Cortez P, Lewis MG, Cairns S, Mackall C, Franchini G. Recombinant interleukin-7 induces proliferation of naive macaque CD4<sup>+</sup> and CD8<sup>+</sup> T cells in vivo. *J Virol* 2004 Sep;78(18):9740-49.
  200. Younis I, Khair L, Dundr M, Lairmore MD, Franchini G, Green PL. Repression of human T-cell leukemia virus type 1 and type 2 replication by a viral mRNA-encoded posttranscriptional regulator. *J Virol*. 2004 Oct;78(20):11077-83.
  201. Price DA, West SM, Betts MR, Ruff LE, Brenchley JM, Ambrozak DR, Edghill-Smith Y, Kuroda MJ, Bogdan D, Kunstman K, Letvin NL, Franchini G, Wolinsky SM, Koup RA, Douek DC. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. *Immunity*. 2004 Dec;21(6):793-803.
  202. Nicot C, Dundr M, Johnson JM, Fullen JR, Alonzo N, Fukumoto R, Princler GL, Derse D, Misteli T, Franchini G.

- Human T cell leukemia/lymphoma virus type 1: playing hide and seek. *AIDS Rev.* 2004 Oct-Dec;6(4):245-247.
203. Edghill-Smith Y, Bray M, Whitehouse CA, Miller D, Mucker E, Manischewitz J, King LR, Robert-Guroff M, Hryniewicz A, Venzon D, Meseda C, Weir J, Nalca A, Livingston V, Wells J, Lewis MG, Huggins J, Zwiers SH, Golding H, Franchini G. Smallpox Vaccine Does Not Protect Macaques with AIDS from a Lethal Monkeypox Virus Challenge. *J Infect Dis.* 2005 Feb 1;191(3):372-81. Epub 2005 Jan 04.
204. Van Rompay KK, Abel K, Lawson JR, Singh RP, Schmidt KA, Evans T, Earl P, Harvey D, Franchini G, Tartaglia J, Montefiori D, Hattangadi S, Moss B, Marthas ML. Attenuated Poxvirus-Based Simian Immunodeficiency Virus (SIV) Vaccines Given in Infancy Partially Protect Infant and Juvenile Macaques Against Repeated Oral Challenge With Virulent SIV. *J Acquir Immune Defic Syndr.* 2005 Feb 1;38(2):124-134.
205. Nacsa J, Edghill-Smith Y, Tsai WP, Venzon D, Tryniszewska E, Hryniewicz A, Moniuszko M, Kinter A, Smith KA, Franchini G. Contrasting Effects of Low-Dose IL-2 on Vaccine-Boosted Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cells in Macaques Chronically Infected with SIVmac251. *J Immunol.* 2005 Feb 15;174(4):1913-21.
206. Moniuszko M, Bogdan D, Pal R, Venzon D, Stevceva L, Nacsa J, Tryniszewska E, Edghill-Smith Y, Wolinsky S, Franchini G. Correlation between viral RNA levels but not immune responses in plasma and tissues of macaques with long-standing SIVmac251 infection. *Virology.* 2005 Mar 1;333(1):159-168.
207. Murphy E, Jacobson S, Franchini G, Taylor GP, Hanchard B, Morgan O, Lairmore M. International Retrovirology Association brings together scientists and clinicians to bridge discoveries about human T-lymphotropic viruses from the laboratory to clinical trials. *Retrovirology.* 2005 Mar 29;2(1):22.
208. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE, Reimann KA, Franchini G. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. *Nat Med.* 2005 Jul;11(7):740-747.
209. Vaccari M, Trindade CJ, Venzon D, Zanetti M, Franchini G. Vaccine-Induced CD8+ Central Memory T Cells in Protection from Simian AIDS. *J Immunol.* 2005 Sep 15;175(6):3502-7.
210. Nicot C, Harrod RL, Ciminale V, Franchini G. Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions. *Oncogene.* 2005 Sep 5;24(39):6026-34.
211. Hel Z, Tsai WP, Tryniszewska E, Nacsa J, Markham PD, Lewis MG, Pavlakis GN, Felber BK, Tartaglia J, Franchini G. Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. *J Immunol.* 2006 Jan 1;176(1):85-96.
212. Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, Moniuszko M, Hel Z, Belyakov IM, Berzofsky JA, Parks RW, Markham PD, Letvin NL, Tartaglia J, Franchini G. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T cell loss and reduces both systemic and mucosal SHIVKU2 RNA levels. *J Virol.* 2006 Apr;80(8):3732-42.
213. Belyakov IM, Kuznetsov VA, Kelsall B, Klinman D, Moniuszko M, Lemon M, Markham PD, Pal R, Clements JD, Lewis MG, Strober W, Franchini G, Berzofsky JA. Impact of vaccine-induced mucosal high avidity CD8+ CTL in delay of AIDS-viral dissemination from mucosa. *Blood.* 2006 Apr 15;107(8):3258-3264.
214. Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G. Subunit Recombinant Vaccine Protects against Monkeypox. *J Immunol.* 2006 Aug 15;177(4):2552-64.
215. Zanetti M, Franchini G. T cell memory and protective immunity by vaccination: is more better? *Trends Immunol.* 2006 Nov;27(11):511-7. Epub 2006 Sep 25.
216. Boasso A, Vaccari M, Nilsson J, Shearer GM, Andersson J, Cecchinato V, Chougnet C, Franchini G. Do regulatory T-cells play a role in AIDS pathogenesis? *AIDS Rev.* 2006 Jul-Sep;8(3):141-7.
217. Mario Clerici, Monica Vaccari, Adriano Boasso, Valentina Cecchinato, Gene Shearer, and Genoveffa Franchini. The PD-1/PDL-1 pathway: another magic bullet for HIV therapy? *Hot News column. AIDS Rev.* 2006 Oct-Nov;8(4):173-
218. Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai WP, Heraud JM, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G. CTLA-4 blockade decreases TGF- $\beta$ , indoleamine 2,3- dioxygenase, and viral RNA expression in tissues of SIVmac251-infected macaques. *Blood.* 2006 Dec;108(12):3834-42.
219. Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, Shearer GM, Andersson J, Chougnet C. HIV-1 driven regulatory T cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. *Blood.* 2006 Dec 1;108(12):3808-17.
220. Moniuszko M, Edghill-Smith Y, Venzon D, Stevceva L, Nacsa J, Tryniszewska E, Tsai WP, Franchini G. Decreased number of CD4(+) and CD8(+) T cells that express the interleukin-7 receptor in blood and tissues of SIV-infected macaques. *Virology.* 2006 Dec;356(1-2):188-97.

221. Ghorbel S, Sinha-Datta U, Dunder M, Brown M, Franchini G, Nicot C. Human T-cell Leukemia Virus Type I p30 Nuclear/Nucleolar Retention Is Mediated through Interactions with RNA and a Constituent of the 60 S Ribosomal Subunit. *J Biol Chem*. 2006 Dec 1;281(48):37150-8. Epub 2006 Sep 28.
222. von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, Franchini G, Albert PS, Bischofberger N, Boyer JD, Weiner DB, Markham P, Israel ZR, Eldridge JH, Pavlakis GN, Felber BK. Long-lasting Decrease of Viremia in Chronically SIVmac251-infected Macaques After Therapeutic DNA Immunization. *J Virol*. 2007 Feb;81(4):1972-9. Epub 2006 Nov 29.
223. Lairmore MD, Franchini G. Human T-cell leukemia/lymphoma virus types 1 and 2. In Knipe DM, Howley PM (Eds.): *Fields Virology*. Philadelphia, Lippincott Williams & Wilkins, 2007, pp. 2071-2106.
224. Hryniewicz A, Price DA, Moniuszko M, Boasso A, Edghill-Spano Y, West SM, Venzon D, Vaccari M, Tsai WP, Tryniszewska E, Nacsa J, Villinger F, Ansari AA, Trindade CJ, Morre M, Brooks D, Arlen P, Brown HJ, Kitchen CM, Zack JA, Douek DC, Shearer GM, Lewis MG, Koup RA, Franchini G. Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virusmac251-infected macaques. *J Immunol*. 2007 Mar 15;178(6):3492-504.
225. Petrovas C, Price DA, Mattapallil J, Ambrozak DR, Geldmacher C, Cecchinato V, Vaccari M, Tryniszewska E, Gostick E, Roederer M, Douek DC, Morgan SH, Davis SJ, Franchini G, Koup RA. SIV-specific CD8+T-cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. *Blood*. 2007 Aug 1;110(3):928-36. Epub 2007 Apr 17.
226. Fukumoto R, Dunder M, Nicot C, Adams A, Valeri VW, Samelson LE, Franchini G. Inhibition of TCR Signal Transduction and Viral Expression by the Linker for Activation of T Cells–Interacting p12I Protein of HTLV-1. *J Virol*. 2007 Sep;81(17):9088-99. Epub 2007 Jun 20.
227. Boasso A, Vaccari M, Hryniewicz A, Fuchs D, Nacsa J, Cecchinato V, Andersson J, Franchini G, Shearer GM, Chougnat C. Regulatory T cell markers, indoleamine (2,3)-dioxygenase and virus levels in spleen and gut during progressive SIV infection. *J Virol*. 2007 Sep;81(17):9088-99. Epub 2007 Jun 20.
228. Cecchinato V, Tryniszewska E, Ma ZM, Vaccari M, Boasso A, Tsai WP, Petrovas C, Fuchs D, Heraud JM, Venzon D, Shearer GM, Koup RA, Lowy I, Miller CJ, Franchini G. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. *J Immunol*. 2008 Apr 15;180 (8):5439-47.
229. Valentina Cecchinato, Christopher J. Trindade, Arian Laurence, Jean Michel Heraud, Jason Brenchley, Elzbieta Tryniszewska, Maria Grazia Ferrari, Wen-Po Tsai, Monica Vaccari, Robyn Washington Parks, David Venzon, Daniel C. Douek, John J. O’Shea, and Genoveffa Franchini. Altered balance between Th17 and Th1 T-cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus infected macaques. *Mucosal Immunology*, 2008 May; 1, 279 - 288 (01 Jul 2008), doi: 10.1038/mi.2008.14, Article
230. Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH. Differential Antigen Requirements for Protection Against Systemic and Intranasal Vaccinia Virus Challenges in Mice. *Journal of Virology*, July 2008, p. 6829-6837, Vol. 82, No. 140022-538X/08/\$08.00+0doi:10.1128/JVI.00353-08
231. Fukumoto R, Andresen V, Bialuk I, Cecchinato V, Walser JC, Valeri VW, Nauroth JM, Gessain A, Nicot C, Franchini G. In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein. *Blood*. 2009 Apr 16;113(16):3726-34. doi: 10.1182/blood-2008-04-146928. Epub 2008 Sep 12. PubMed PMID: 18791162; PubMed Central PMCID: PMC2670790.
232. Vaccari M., Mattapallil J., Song K., Tsai W.P., Hryniewicz A., Venzon D., Zanetti M., Reimann K.A., Roederer M., Franchini G. Reduced protection from Simian Immunodeficiency Virus SIVmac251 infection afforded by memory CD8+T-cells induced by vaccination during CD4+T-cell deficiency. *J Virol* 2008 Oct; 9629-9638
233. Vaccari M., Boasso A., Ma Z.M., Cecchinato V., Venzon D., Doster M.N. Tsai W. P. Shearer G.M., Fuchs D., Felber B, Pavlakis G, Miller J.C., Franchini G., CD4+ T-cell Loss and Delayed Expression of modulators of Immune Responses at Mucosal Sites of Vaccinated Macaques following SIVmac251 infection. *Mucosal Immunology*, **Mucosal Immunology** 2008 Nov 1, 497–507; doi:10.1038/mi.2008.60; Epub 2008 Sep 17.
234. Genoveffa Franchini et. al. Unsung Hero Robert C. Gallo. **SCIENCE** [www.sciencemag.org](http://www.sciencemag.org), 2009 Jan VOL 323
235. Jean-Philippe Herbeuval, Jakob Nilsson, Adriano Boasso, Jean-Philippe Herbeuval, Jakob Nilsson, Adriano Boasso, Andrew W. Hardy, Monica Vaccari, Valentina Cecchinato, Valerio Valeri, Genoveffa Franchini, Jan Andersson, Gene M. Shearer, HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and SIV-infected macaques. *Concise Communication. AIDS* 2009 Jan, 23:35-40
236. Monica Vaccari and Genoveffa Franchini, HIV vaccines: What are we learning from failure? Hot News column, *AIDS Rev*. 2009, 10:255
237. Franchini G, Choosing the right memory T cell for HIV. News & Views: *Nat Med*. 2009 Mar;15(3):244-6.

238. Boasso A, Vaccari M, Fuchs D, Hardy AW, Tsai WP, Tryniszewska E, Shearer GM, Franchini G. Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques. *J Immunol*. 2009 Apr 1;182(7):4313-20. doi: 10.4049/jimmunol.0803314. PubMed PMID: 19299731.
239. Miriam Poirier, Ofelia A Olivero, Andrew W. Hardy, Genoveffa Franchini, Jennifer P Borrojerdi, Vernon E Walker, Dale M Walker, and Gene M Sharer, Antiretroviral Activity of the Aminothiol WR1065 Against Human Immunodeficiency Virus (HIV-1) *in vitro* and Simian Immunodeficiency Virus (SIV) *ex vivo*; *Journal of AIDS Research and Therapy* 2009 Nov 6;6:24. doi: 10.1186/1742-6405-6-24. PubMed PMID: 19895691; PubMed Central PMCID: PMC2777914.
240. Maria E. Moreno-Fernandez, Wildeman Zapata, Jason T., Blackard, Genoveffa Franchini, and Claire A. Chougnet Human Regulatory T Cells Are Targets for Human Immunodeficiency Virus (HIV) Infection, and Their Susceptibility Differs Depending on the HIV Type 1 Strain. *Journal of Virology*; 2009 Dec;83(24):12925-33. doi: 10.1128/JVI.01352-09. Epub 2009 Oct 14
241. Magdalini Moutaftsi, David Tschärke, David Koelle, Lichen Jing, Larry Stern, Mauricio Calvocalle, Francis Ennis, Masanori Terajima, Gerd Sutter, Shane Crotty, Ingo Drexler, Genoveffa Franchini, Jon Yewdell, Steve Heads, Janice Blum, Kerrie, Vaughan, Jay Greenbaum, Erika Assarsson, Carla Oseroff, Bjoern Peters, John Sidney, Howard Grey, Alex Sette. Vaccinia virus leads the way: Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. *Future Microbiol*. 2010 Feb;5(2):221-39
242. Gordon SN, Weissman AR, Cecchinato V, Fenizia C, Ma ZM, Lee TH, Zaffiri L, Andresen V, Parks RW, Jones KS, Heraud JM, Ferrari MG, Chung HK, Venzon D, Mahieux R, Murphy EL, Jacobson S, Miller CJ, Ruscetti FW, Franchini G. Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques. *Journal of Virology*. 2010 Mar;84(6):3043-58
243. Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M, Venzon D, Klinman D, Strober W, Kelsall B, Franchini G, Belyakov IM, Berzofsky JA. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. *Proc Natl Acad Sci U S A*. 2010 May 25;107(21):9843-8
244. Vaccari M & G Franchini. Memory T-cells in Rhesus Macaques. In: Memory cells: *Adv Exp Med Biol*. 2010;684:126-44.
245. Valerio W. Valeri, Anna Hryniewicz, Vibeke Andresen, Kathy Jones, Claudio Fenizia, Izabela Bialuk, Hye Kyung Chung, Risaku Fukumoto, Robyn Washington Parks, Maria Grazia Ferrari, Christophe Nicot, Valentina Cecchinato, Frank Ruscetti and Genoveffa Franchini, Requirement of the Human T-cell Leukemia Virus p12 and p30 Genes for Infectivity of Human Dendritic Cells and Macaques but not Rabbits, *Blood*, Jul 20, 2010; doi:10.1182/blood-2010-05-284141
246. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. *Expert Rev Vaccines*. 2010 Sep;9(9):997-1005. Review.
247. Van Prooyen N, Andresen V, Gold H, Bialuk I, Pise-Masison C, Franchini G, Hijacking the T-cell communication network by the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p12 and p8 proteins. *Mol Aspects Med*. 2010 Oct;31(5):333-43. Epub 2010 Jul 29.
248. Van Prooyen N, Gold H, Andresen V, Schwartz O, Jones K, Ruscetti F, Lockett S, Gudla P, Venzon D, Franchini G. Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission *Proc Natl Acad Sci U S A*. 2010 Nov 30;107(48):20738-43. Epub 2010 Nov 12.
249. Strbo N, Vaccari M, Pahwa S, Kolber MA, Fisher E, Gonzalez L, Doster MN, Hryniewicz A, Felber BK, Pavlakis GN, Franchini G, Podack ER. Gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa. *Vaccine*. 2011 Mar 21;29(14):2619-25. pub 2011 Jan 28.
250. Gordon SN, Cecchinato V, Andresen V, Heraud JM, Hryniewicz A, Parks RW, Venzon D, Chung HK, Karpova T, McNally J, Silvera P, Reimann KA, Matsui H, Kanehara T, Shinmura Y, Yokote H, Franchini G. Smallpox vaccine safety is dependent on T cells and not B cells. *J Infect Dis*. 2011 Apr 15;203(8):1043-53. doi: 10.1093/infdis/jiq162. PubMed PMID: 21450994; PubMed Central PMCID: PMC3068024.
251. Edwards D, Fenizia C, Gold H, de Castro-Amarante MF, Buchmann C, Pise-Masison CA, Franchini G. Orf-I and Orf-II-Encoded Proteins in HTLV-1 Infection and Persistence. *Viruses*. 2011 Jun;3(6):861-85. Epub 2011 Jun 17.
252. Andresen V, Pise-Masison CA, Sinha-Datta U, Bellon M, Valeri V, Washington Parks R, Cecchinato V, Fukumoto R, Nicot C, Franchini G. Suppression of HTLV-1 replication by Tax-mediated rerouting of the p13 viral protein to nuclear speckles. *Blood*. 2011 Aug 11;118(6):1549-59. Epub 2011 Jun 15.
253. Fenizia C, Keele BF, Nichols D, Cornara S, Binello N, Vaccari M, Pegu P, Robert-Guroff M, Ma ZM, Miller CJ, Venzon D, Hirsch V, Franchini G. TRIM5 $\alpha$  does not affect SIVmac251 replication in vaccinated or unvaccinated Indian Rhesus Macaques following intrarectal challenge exposure. *J Virol*. 2011 Sep 14.

254. Dustin C. Edwards, Katherine M. McKinnon, Claudio Fenizia, Kyung-Jin Jung, John N. Brady, and Cynthia A. Pisoni. Inhibition of Geranylgeranyl Transferase-I Decreases Cell Viability of HTLV-1-Transformed Cells *Viruses* 2011 Oct, 3, 1815-1835; doi:10.3390/v3101815
255. Tosi G, Forlani G, Andresen V, Turci M, Bertazzoni U, Franchini G, Poli G, Accolla RS. Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication. *J Virol*. 2011 Oct;85(20):10719-29. Epub 2011 Aug 3.
256. Pallikkuth S, Rogers K, Villinger F, Doster M, Vaccari M, Franchini G, Pahwa R, Pahwa S. Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication. *Vaccine*. 2011 Nov 15;29(49):9229-38. Epub 2011 Oct 11.
257. Bialuk I, Whitney S, Andresen V, Florese RH, Nacsa J, Cecchinato V, Valeri VW, Heraud JM, Gordon S, Parks RW, Montefiori DC, Venzon D, Demberg T, Guroff MR, Landucci G, Forthal DN, Franchini G. Vaccine Induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques *Vaccine*. 2011 Dec; Oct 27. [Epub ahead of print]
258. Sui Y, Gagnon S, Dzutsev A, Zhu Q, Yu H, Hogg A, Wang Y, Xia Z, Belyakov IM, Venzon D, Klinman D, Strober W, Kelsall B, Franchini G, Berzofsky JA. TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4(+) memory T cell loss in SIVmac251-challenged rhesus macaques. *Vaccine*. 2011 Dec 9
259. Shari N. Gordon, Rhonda C. Kines, Galyna Kutsyna, Zhong-Min Ma, Anna Hryniewicz, Jeffery N. Roberts, Claudio Fenizia, Rachmat Hidajat, Nicolas Cuburu, Christopher B. Buck, Marcelino L. Bernardo, Marjorie Robert-Guroff, Christopher J. Miller, Barney S. Graham, Douglas R. Lowy, John T. Schiller, and Genoveffa Franchini, Targeting the Vaginal Mucosa with Human Papillomavirus Pseudovirion Vaccines delivering SIV DNA, *J Immunol*. 2012 Jan 15;188(2):714-23. Epub 2011 Dec 14.
260. Vaccari M, Boasso A, Fenizia C, Fuchs D, Hryniewicz A, Morgan T, Weiss D, Doster MN, Heraud JM, Shearer GM, Franchini G. Fatal pancreatitis in SIVmac251 infected macaques treated with 2',3'-dideoxyinosine (ddI) and 2' dideoxy-3' deoxythymidine(d4T) following CTLA-4 and IDO blockade. *J Virol*. 2012 86: 108-13, doi: 10.1128/JVI.05609-11
261. Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick E, Price DA, Waldmann TA, Restifo NP, Franchini G, Roederer M. Superior T memory stem cell persistence supports long-lived T cell memory. *J Clin Invest*. 2013 Feb 1;123(2):594-9. doi: 10.1172/JCI66327. Epub 2013 Jan 2. PubMed PMID: 23281401; PubMed Central PMCID: PMC3561805.
262. Poonam Pegu, Monica Vaccari, Shari Gordon, Brandon F. Keele, Melvin Doster, Youngjun Guan, Guido Ferrari, Ranajit Pal, Maria Grazia Ferrari, Stephen Whitney, Lauren Hudacik, Erik Billings, Mangala Rao, David Montefiori, Claudio Fenizia, Jeffrey D. Lifson, Donald Stablein, Jim Tartaglia, Nelson Michael, Jerome Kim, David Venzon & Genoveffa Franchini, Antibodies with high avidity to the gp120 envelope protein in protection from SIV<sub>mac251</sub> acquisition in an immunization regimen that mimics the RV-144 Thai Trial, *J Virol*, 2013 Feb;87(3):1708-19. doi: 10.1128/JVI.02544-12. Epub 2012 Nov 21.
263. Daniel Mendoza, Stephen A. Migueles, Julia E. Rood, Bennett Peterson, Sarah Johnson, Nicole Doria-Rose, Douglas Schneider, Eva Rakasz, Matthew T. Trivett, Charles M. Trubey, Vicky Coalter, David Watkins, Genoveffa Franchini, Jeffrey D. Lifson, and Mark Connors. Cytotoxicity Capacity of SIV-Specific CD8<sup>+</sup> T Cells Against Primary Autologous Targets Correlates with Immune Control in SIV-Infected Rhesus Macaques, *PLoS Pathog*. 2013 Feb;9(2):e1003195. doi: 10.1371/journal.ppat.1003195. Epub 2013 Feb 28.
264. Richard M. Dunham, Shari N. Gordon, Monica Vaccari, Michael Piatak, Yong Huang, Steven G. Deeks, Jeffrey Lifson, Genoveffa Franchini, Joseph M. McCune, Preclinical Evaluation of HIV Eradication in the SIV-infected Rhesus Macaque: a Pilot Study Testing Inhibition of Indoleamine 2,3-Dioxygenase, *AIDS Research and Human Retroviruses*, 2013 Feb; 28:1089, Epub 2012
265. Monica Vaccari, Brandon F. Keele, Steven E. Bosinger, Melvin Doster, Zhong-Min Ma, Justin Pollara, Anna Hryniewicz, Guido Ferrari, Youngjun Guan, Donald Forthal, David Venzon, Claudio Fenizia, Tia Morgan, David Montefiori, Jeffrey D. Lifson, Chris Miller, Guido Silvestri, Margherita Rosati, Barbara K. Felber, George N. Pavlakis, James Tartaglia, and Genoveffa Franchini, Protection afforded by a HIV vaccine candidate in macaques dependent on the dose of SIV<sub>mac251</sub> challenge exposure., *J Virol*. 2013 Mar;87(6):3538-48. doi: 10.1128/JVI.02863-12. Epub 2013 Jan 16.
266. Monica Vaccari, Rabih Halwani, L. Jean Patterson, Adriano Boasso, Jennifer Beal, Elzbieta Tryniszewska, Anna Hryniewicz, David Venzon, Elias Haddad, Mohamed El-Far, Margherita Rosati, George N. Pavlakis, Barbara K. Felber, Saleh Al-Muhsen, Marjorie Robert-Guroff, Rafick-Pierre Sekaly & Genoveffa Franchini. Antibodies to gp120 and PD-1 Expression on Virus-Specific CD8<sup>+</sup> T-cells in Protection from Simian AIDS, *J Virol*. 2013 Mar;87(6):3526-37. doi: 10.1128/JVI.02686-12. Epub 2013 Jan 16.



267. Natasa Strbo, Monica Vaccari, Savita Pahwa, Michael A. Kolber, Melvin N. Doster, Eva Fisher, Louis Gonzalez, Donald Stablein, Genoveffa Franchini, Eckhard R. Podack. Novel vaccination modality provides significant protection against mucosal infection by highly pathogenic SIV. *J Immunol.* 2013 Mar 15;190(6):2495-9. doi: 10.4049/jimmunol.1202655. Epub 2013 Feb 11
268. Sui Y, Gordon S, Berzofsky JA., Franchini G, Nonhuman Primate Models for HIV/AIDS Vaccine Development., *Curr Protoc Immunol.* 2013 Oct 1 1;102:12.14.1-12.14.30. doi: 10.1002/0471142735.im1214s102.
269. Fenizia C, Fiocchi M, Jones K, Parks RW, Ceribelli M, Chevalier SA, Edwards D, Ruscetti F, Pise-Masison CA, Franchini G. Human T-cell leukemia/lymphoma virus type 1 p30, but not p12/p8, counteracts toll-like receptor 3 (TLR3) and TLR4 signaling in human monocytes and dendritic cells. *J Virol.* 2014 Jan;88(1):393-402. doi: 10.1128/JVI.01788-13. Epub 2013 Oct 23. PubMed PMID: 24155397; PubMed Central PMCID: PMC3911690.
270. Edwards D, Fukumoto R, de Castro-Amarante MF, et al. Palmitoylation and p8-Mediated Human T-Cell Leukemia Virus Type 1 Transmission. *Journal of Virology.* 2014 Feb;88(4):2319-2322. doi:10.1128/JVI.03444-13. Epub 2013 Nov 27., PMID: 24284316, February 2014
271. Jeffrey E. Teigler, Jim Tartaglia, Sanjay Phogat, Genoveffa Franchini, Vanessa M. Hirsch, Nelson L. Michael, and Dan H. Barouch, The Canarypox Vector ALVAC Induces Higher Cytokine Responses Compared to the Vaccinia-Based Vectors MVA and NYVAC in Rhesus Monkeys, *J Virol.* 2014 Feb; 88(3):1809-14. doi: 10.1128/JVI.02386-14
272. Liyanage NP, Gordon SN, Doster MN, Pegu P, Vaccari M, Shukur N, Schifanella L, Pise-Masison CA, Lipinska D, Grubczak K, Moniuszko M, Franchini G. Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac<sub>251</sub> infection of macaques. *Virology.* 2014 Feb;450-451:359-68. doi: 10.1016/j.virol.2013.12.003. Epub 2014 Jan 21. PubMed PMID: 24503100.
273. Monica Vaccari, Claudio Fenizia, Zhong-Min Ma, Anna Hryniewicz, Adriano Boasso, Melvin N Doster, Christopher J. Miller, Niklas Lindegardh, Joel Tarning, Alan L Landay, Gene M Shearer & Genoveffa Franchini, Transient increase of interferon-stimulated genes and no clinical benefit by Chloroquine treatment during acute SIV infection of macaques. *AIDS Res Hum Retroviruses.* 2014 Apr;30(4):355-62. doi: 10.1089/AID.2013.0218. Epub 2013 Dec 24.
274. Sui Y, Hogg A, Wang Y, Frey B, Yu H, Xia Z, Venzon D, McKinnon K, Smedley J, Gathuka M, Klinman D, Keele BF, Langermann S, Liu L, Franchini G, Berzofsky JA. Vaccine-induced myeloid cell population dampens protective immunity to SIV. *J Clin Invest.* 2014 Jun 2;124(6):2538-49. doi: 10.1172/JCI73518. Epub 2014 May 16
275. Berzofsky, J. A., and G. Franchini. 2014. Human/simian immunodeficiency virus transmission and infection at mucosal sites. In *Mucosal Immunology, 4<sup>th</sup> Edition*, Mestecky, J., M. W. Russell, B. L. Kelsall, P. L. Ogra, W. Strober, B.N. Lambrecht, and H. Cheroutre, editors. Elsevier, Amsterdam
276. Vargas-Inchaustegui DA, Tuero I, Mohanram V, Musich T, Pegu P, Valentin A, Sui Y, Rosati M, Bear J, Venzon DJ, Kulkarni V, Alicea C, Pilkington GR, Liyanage NP, Demberg T, Gordon SN, Wang Y, Hogg AE, Frey B, Patterson LJ, DiPasquale J, Montefiori DC, Sardesai NY, Reed SG, Berzofsky JA, Franchini G, Felber BK, Pavlakis GN, Robert-Guroff M. Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. *Clin Immunol.* 2014 Aug;153(2):308-22. doi: 10.1016/j.clim.2014.05.008. Epub 2014 Jun 4. PubMed PMID: 24907411; PubMed Central PMCID: PMC4102324.
277. Pise-Masison CA, de Castro-Amarante MF, Enose-Akahata Y, Buchmann RC, Fenizia C, Washington Parks R, Edwards D, Fiocchi M, Alcantara LC Jr, Bialuk I, Graham J, Walser JC, McKinnon K, Galvão-Castro B, Gessain A, Venzon D, Jacobson S, Franchini G. Co-dependence of HTLV-1 p12 and p8 functions in virus persistence. *PLoS Pathog.* 2014 Nov 6;10(11):e1004454. doi: 10.1371/journal.ppat.1004454. eCollection 2014 Nov. PubMed PMID: 25375128; PubMed Central PMCID: PMC4223054.
278. Valentin A, McKinnon K, Li J, Rosati M, Kulkarni V, Pilkington GR, Bear J, Alicea C, Vargas-Inchaustegui DA, Jean Patterson L, Pegu P, Liyanage NP, Gordon SN, Vaccari M, Wang Y, Hogg AE, Frey B, Sui Y, Reed SG, Sardesai NY, Berzofsky JA, Franchini G, Robert-Guroff M, Felber BK, Pavlakis GN. Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. *Clin Immunol.* 2014 Nov;155(1):91-107. doi: 10.1016/j.clim.2014.09.005. Epub 2014 Sep 16. PubMed PMID: 25229164; PubMed Central PMCID: PMC4252823.
279. Gordon SN, Doster MN, Kines RC, Keele BF, Brocca-Cofano E, Guan Y, Pegu P, Liyanage NP, Vaccari M, Cuburu N, Buck CB, Ferrari G, Montefiori D, Piatak M Jr, Lifson JD, Xenophontos AM, Venzon D, Robert-Guroff M, Graham BS, Lowy DR, Schiller JT, Franchini G. Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. *J Immunol.* 2014 Dec 15;193(12):6172-83. doi: 10.4049/jimmunol.1401504. Epub 2014 Nov 14. PubMed PMID: 25398324.
280. Selinger C, Strbo N, Gonzalez L, Aicher L, Weiss JM, Law GL, Palermo RE, Vaccari M, Franchini G, Podack ER, Katze MG. Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome. *Clin Vaccine Immunol.* 2014 Dec; 21(12):1650-60. doi: 10.1128/CVI.00455-14. Epub 2014 Oct 1. PubMed PMID: 25274805; PubMed Central PMCID: PMC4248781.

281. Gupta S, Pegu P, Venzon DJ, Gach JS, Ma ZM, Landucci G, Miller CJ, Franchini G, Forthal DN. Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge. *J Infect Dis*. 2015 Jan 1;211(1):45-52. doi: 10.1093/infdis/jiu300. Epub 2014 May 21. PubMed PMID: 24850790.
282. Moniuszko M, Liyanage NP, Doster MN, Parks RW, Grubczak K, Lipinska D, McKinnon K, Brown C, Hirsch V, Vaccari M, Gordon S, Pegu P, Fenizia C, Flisiak R, Grzeszczuk A, Dabrowska M, Robert-Guroff M, Silvestri G, Stevenson M, McCune J, Franchini G. Glucocorticoid Treatment at Moderate Doses of SIV<sub>mac251</sub>-Infected Rhesus Macaques Decreases the Frequency of Circulating CD14(+)CD16(++) Monocytes But Does Not Alter the Tissue Virus Reservoir. *AIDS Res Hum Retroviruses*. 2015 Jan; 31(1):115-26. doi: 10.1089/AID.2013.0220. PubMed PMID: 24432835; PubMed Central PMCID: PMC4287193.
283. Blackburn M, Ma ZM, Caccuri F, McKinnon K, Schifanella L, Yongjun G, Gorini G, Venzon D, Fenizia C, Binello N, Gordon SN, Miller CJ, Franchini G, and Vaccari M. Regulatory and helper follicular T cells differently affect antibody avidity to 2 SIV-gp120 *J Immunol* 2015 Oct 1;195(7):3227-36. doi: 10.4049/jimmunol.1402699
284. de Castro-Amarante MF, Pise-Masison CA, McKinnon K, Washington Parks R, Galli V, Omsland M, Andresen V, Massoud R, Brunetto G, Caruso B, Venzon D, Jacobson S, Franchini G. HTLV-1 infection of the three monocyte subsets contributes to viral burden in humans. *J Virol*. 2015 Nov 25. pii: JVI.02735-15. PMID: 26608313
285. Barreto FK, Khouri R, de Almeida Rego FF, de Castro-Amarante MF, Bialuk I, Pise-Masison CA, Galávo-Castro B, Gessain A, Jacobson S, Franchini G, Carlos Jr Alcantara L. ORFI genetic polymorphisms in geographically distinct HTLV-1 infections *Retrovirology*. 2015; 12(Suppl 1): P55. PMCID: PMC4578275 Published online 2015 Aug 28. doi: 10.1186/1742-4690-12-S1-P55
286. Musich T, Demberg T, Morgan IL, Estes JD, Franchini G, and Robert-Guroff M, Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques., *Clin Immunology*, PMID: 25840105 2015 Jun;158(2):127-39. doi: 10.1016/j.clim.2015.03.020. Epub 2015 Apr 1.
287. Fouts TR, Bagley K, Prado IJ, Bobb KL, Schwartz JA, Xu R, Zagursky RJ, Egan MA, Eldridge JH, LaBranche CC, Montefiori DC, Le Buanec H, Zagury D, Pal R, Pavlakis GN, Felber BK, Franchini G, Gordon S, Vaccari M, Lewis GK, DeVico AL, Gallo RC. *Proc Natl Acad Sci USA* PMID: 25681373 2015 Mar 3;112(9):E992-9. doi: 10.1073/pnas.1423669112. Epub 2015 Feb 13.
288. Tuero I, Mohanram V, Musich T, Miller L, Vargas-Inchaustegui D, Demberg T, Venzon D, Kalisz I, Rao M, Vaccari M, Franchini G, Barnett S, Robert-Guroff. Mucosal B cells are associated with delayed SIV acquisition in vaccinated female but not male rhesus macaques following SIV<sub>mac251</sub> rectal challenge. *PLoS Path* PMID: 26267144 2015 Aug 12;11(8):e1005101. doi: 10.1371/journal.ppat.1005101. eCollection 2015.
289. Rende F, Cavallari I, Andersen V, Valeri VW, D'Agostino D, Franchini G, Ciminale V. Identification of novel monocistronic HTLV-1 mRNAs encoding f1 unctional Rex isoforms *Retrovirology* PMID: 26133546 2015 Jul 2;12:58. doi: 10.1186/s12977-015-0184-2.
290. Cavallari I, Rende F, Bona MK, Sztuba-Solinska J, Silic-Benussi M, Tognon M, LeGrice SF, Franchini G, D'Agostino DM, Ciminale V. Expression Of Alternatively Spliced Htlv-1 Mrnas Is Influenced By Mitosis And By A Novel Cis-Acting Regulatory Sequence. (JVIO2298-15R1). *J Virol*. 2015 Nov 18. pii: JVI.02298-15. PMID: 26581997
291. Brown EP, Normandin E, Osei-Owusu NY, Mahan AE, Chan YN, Lai JI, Vaccari M, Rao M, Franchini G, Alter G, Ackerman ME. Microscale purification of antigen-specific antibodies. *J Immunol Methods*. 2015 Oct;425:27-36. doi: 10.1016/j.jim.2015.06.005. Epub 2015 Jun 12. PMID: 26078040

#### Submitted and in Editing:

292. Vaccari et al. Adjuvant dependent innate and adaptive immune signature correlates with reduced risk of SIV<sub>mac251</sub> acquisition *Nat Med*, in press
293. Gurgo C, Fenizia C, McKinnon K, Fabozzi G, and Franchini G. Episomal HIV DNA: A hidden target for HIV eradication? **submitted**

#### WORK SUPPORTED BY FRANCHINI LABORATORY

1. Mahieux, R., Pise-Masison, C.A., Lambert, P.F., Nicot, C., De Marchis, L., Gessain, A., Green, P., Hall, W.W., and Brady, J.N.: Differences in the ability of HTLV-1 and HTLV-2 Tax to inhibit p53 function. *Journal of Virology* 74:6866-6874, 2000.
2. Nicot, C., and Harrod, R.: Distinct p300-responsive mechanisms promote caspase-dependent apoptosis by human T-

- cell lymphotropic virus type 1 tax protein. *Molecular and Cellular Biology* 20:8580-8589, 2000.
3. Mordelet E, Mahieux R, Nicot C, Ozden S. HTLV-I-associated pathogenesis: involvement of Tax protein. *Recent Res Devel Virol.* 2001 3:177-89.
  4. Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T, Nicot C. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. *Blood* 2001 Dec 15;98(13):3762-3769.
  5. Arnulf B, Villemain A, Nicot C, Mordelet E, Charneau P, Kersual J, Zermati Y, Mauviel A, Bazarbachi A, Hermine O. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. *Blood* 2002 Dec 1;100(12):4129-4138.
  6. Edwards DC, McKinnon KM, Fenizia C, Jung KJ, Brady JN, Pise-Masison CA. Inhibition of geranylgeranyl transferase-I decreases cell viability of HTLV-1-transformed cells. *Viruses.* 2011 Oct;3(10):1815-35. doi: 10.3390/v3101815. Epub 2011 Oct 10. PubMed PMID: 22069517; PubMed Central PMCID: PMC3205383.
  7. Chevalier SA, Durand S, Dasgupta A, Radonovich M, Cimarelli A, Brady JN, Mahieux R, Pise-Masison CA. The transcription profile of Tax-3 is more similar to Tax-1 than Tax-2: insights into HTLV-3 potential leukemogenic properties. *PLoS One.* 2012;7(7):e41003. doi: 10.1371/journal.pone.0041003. Epub 2012 Jul 20. PubMed PMID: 22911729; PubMed Central PMCID: PMC3401231.
  8. Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. *Blood.* 2013 Mar 14;121(11):2029-37. doi: 10.1182/blood-2012-05-427773. Epub 2013 Jan 15. PubMed PMID: 23321252; PubMed Central PMCID: PMC3596962.
  9. Chevalier SA, Turpin J, Cachat A, Afonso PV, Gessain A, Brady JN, Pise-Masison CA, Mahieux R. Gem-induced cytoskeleton remodeling increases cellular migration of HTLV-1-infected cells, formation of infected-to-target T-cell conjugates and viral transmission. *PLoS Pathog.* 2014 Feb 27;10(2):e1003917. doi: 10.1371/journal.ppat.1003917. eCollection 2014 Feb. PubMed PMID: 24586148; PubMed Central PMCID: PMC3937318.